['IVACAFTOR/LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['BILIRUBIN' 'UGT1A1' '*28/*28' 'UGT1A1*1, UGT1A1*28' 'OTHER'
 'INCREASED_nan' nan 'PEOPLE' 'DISEASE:NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY' 'nan_RESPONSE' nan
 nan nan 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'CTT/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'MEN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3 + *5 + *2 + *1'
 'CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'nan_CLEARANCE' nan 'PEOPLE' 'DISEASE:HEART_DISEASES'
 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'CYP2C9' '*2 + *3' 'CYP2C9*2, CYP2C9*3' 'DOSAGE'
 'nan_DOSE' nan nan nan 'CAUTION_DOSE_ADJUST']
['CURCUMIN, IVACAFTOR' 'CFTR' 'AA + AG' 'rs77010898' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, TEZACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['MEASLES_VACCINES' 'HLA-DRB1' '*01:01' 'HLA-DRB1*01:01' 'EFFICACY'
 'nan_RESPONSE' nan 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['MEASLES_VACCINES' 'HLA-DRB1' '*08:01' 'HLA-DRB1*08:01' 'EFFICACY'
 'nan_RESPONSE' nan 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['VORICONAZOLE' 'CYP2C19' '*1/*17 + *1/*2 + *17/*17'
 'CYP2C19*1, CYP2C19*2, CYP2C19*17' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['VORICONAZOLE' 'CYP2C19' '*1/*17 + *17/*17 + *1/*2'
 'CYP2C19*1, CYP2C19*2, CYP2C19*17' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['VALPROIC_ACID' 'UGT1A6' '*1a'
 'UGT1A6*1A, UGT1A6*2A, UGT1A6*3A, UGT1A6*4A, UGT1A6*8' 'METABOLISM/PK'
 'nan_METABOLISM' nan 'CHILDREN' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['SIMVASTATIN' 'CYP3A4' '*1/*22 + *22/*22' 'CYP3A4*1, CYP3A4*22'
 'METABOLISM/PK' 'nan_CONCENTRATIONS' nan nan nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' '*6' 'CYP2B6*6' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CLOBAZAM' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'nan_METABOLISM' nan 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' '*1/*1' 'CYP3A4*1, CYP3A4*22' 'METABOLISM/PK'
 'nan_DOSE-ADJUST_TROUGH_CONCENTRATIONS' nan 'PEOPLE'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CAVOSONSTAT' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY' 'nan_RESPONSE'
 nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR/LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR/LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'nan_METABOLISM' nan 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'TYMP' 'AA + AG' 'rs11479' 'DOSAGE'
 'nan_DOSE' nan 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C19' '*2 + *3' 'CYP2C19*2, CYP2C19*3' 'DOSAGE'
 'nan_DOSE' nan 'CHILDREN' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'nan_DOSE' nan 'CHILDREN'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['PRAVASTATIN' 'ACE' 'del/del' 'rs1799752' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE'
 'OTHER:NON-HYPERCHOLESTEROLAEMIC_PATIENTS_SCHEDULED_FOR_ANGIOPLASTY'
 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'CT' 'rs3918290' 'DOSAGE' 'nan_DOSE'
 nan 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'AT' 'rs67376798' 'DOSAGE' 'nan_DOSE'
 nan 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'CG' 'rs75017182' 'DOSAGE' 'nan_DOSE'
 nan 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' nan 'G' 'rs4646458' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['MEASLES_VACCINES' 'HLA-B' '*44:02' 'HLA-B*44:02' 'EFFICACY'
 'nan_RESPONSE' nan 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['ALLOPURINOL' 'HLA-B' '*58:01' 'HLA-B*58:01' 'TOXICITY' 'nan_RESPONSE'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['ESTRONE_SULFATE' 'SLCO1B1' '*5' 'SLCO1B1*1, SLCO1B1*5' 'METABOLISM/PK'
 'INCREASED_nan' nan 'WOMEN' 'OTHER:BREAST_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE' 'nan_DOSE' nan
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOBAZAM' 'CYP2C19' '*2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CLOBAZAM' 'CYP2C19' '*2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CLOBAZAM' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'nan_METABOLISM' nan 'PEOPLE' 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'ABCB1' 'C' 'rs3842' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CLOBAZAM' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'METABOLISM/PK'
 'nan_METABOLISM' nan 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['FLUOROURACIL' 'DPYD' nan 'DEFICIENCY' 'METABOLISM/PK' 'nan_CLEARANCE'
 nan 'PEOPLE' 'DISEASE:HEAD_AND_NECK_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['ENDOXIFEN' 'CYP2D6' nan
 'CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['LAMIVUDINE, NEVIRAPINE, STAVUDINE' 'HLA-B' '*40:01' 'HLA-B*40:01'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL, PRASUGREL, TICAGRELOR' 'CYP2C19' 'A' 'rs4244285' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:ACUTE_CORONARY_SYNDROME'
 'CAUTION_DOSE_ADJUST']
['ENZYME_INHIBITORS' 'CYP19A1' 'CC' 'rs700518' 'OTHER' 'nan_RESPONSE' nan
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['FLECAINIDE' 'CYP2D6' nan 'NORMAL_METABOLIZER' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:TACHYCARDIA, SUPRAVENTRICULAR'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' 'AA + AG' 'rs4244285' 'DOSAGE, EFFICACY'
 'nan_DOSE' nan 'PEOPLE' 'OTHER:PERCUTANEOUS_CORONARY_INTERVENTION'
 'CAUTION_DOSE_ADJUST']
['SIMVASTATIN' 'CYP3A4' '*1/*22 + *22/*22' 'CYP3A4*1, CYP3A4*22'
 'METABOLISM/PK' 'nan_CONCENTRATIONS' nan nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' 'T' 'rs12248560' 'EFFICACY, OTHER' 'nan_RESPONSE'
 nan 'PEOPLE' 'DISEASE:ACUTE_CORONARY_SYNDROME' 'CAUTION_DOSE_ADJUST']
['VORICONAZOLE' 'CYP2C19' '*2 + *17' 'CYP2C19*2, CYP2C19*17' 'DOSAGE'
 'nan_DOSE' nan 'CHILDREN' 'OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' nan 'C' 'rs4646457' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'G' 'rs15524' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'A' 'rs12333983' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'CT' 'rs56038477' 'DOSAGE' 'nan_DOSE'
 nan 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'OR2B11' 'A' 'rs35305980' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'UGT1A10, UGT1A8, UGT1A9' 'del' 'rs3832043' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'UGT1A7' 'G' 'rs17868323' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'ABCB1' 'A' 'rs1045642' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'ABCG2' 'T' 'rs2231142' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['AXITINIB' 'ABCB1' 'T' 'rs2032582' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['IRBESARTAN' 'APOB' 'AG' 'rs1367117' 'EFFICACY, METABOLISM/PK'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['IRBESARTAN' 'APOB' 'GG' 'rs1367117' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'C' 'rs28399499' 'METABOLISM/PK' 'nan_METABOLISM'
 nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' 'A' 'rs4244285' 'EFFICACY, OTHER' 'nan_RESPONSE'
 nan 'PEOPLE' 'DISEASE:ACUTE_CORONARY_SYNDROME' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'ABCB1' 'G' 'rs1045642' 'EFFICACY, OTHER' 'nan_RESPONSE'
 nan 'PEOPLE' 'DISEASE:ACUTE_CORONARY_SYNDROME' 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN' 'APOA5' 'AA' 'rs662799' 'OTHER'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:DYSLIPIDAEMIA' 'CAUTION_DOSE_ADJUST']
['REPAGLINIDE' 'SLCO1B1' 'TT' 'rs4149056' 'METABOLISM/PK' 'nan_EXPOSURE'
 nan 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['GLUCOSE' 'SLCO1B1' 'TT' 'rs4149056' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' nan 'A' 'rs12777823' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' 'MCPH1' 'A' 'rs17570753' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' 'CDH13' 'G' 'rs2116971' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' 'SKOR2' 'G' 'rs9952628' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['QUETIAPINE' 'KCNMA1' 'G' 'rs35793' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' 'MAML3' 'A' 'rs11100483' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'LRP1B' 'G' 'rs874295' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'PSMD14' 'A' 'rs9713' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'AGAP1' 'C' 'rs1869295' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'NPAS3' 'G' 'rs1315115' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'TMEFF2' 'G' 'rs3738883' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['ZIPRASIDONE' 'CDH4' 'A' 'rs4925300' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['ZIPRASIDONE' 'LYN' 'G' 'rs1546519' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['ZIPRASIDONE' 'NALCN' 'C' 'rs9585618' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['ZIPRASIDONE' 'CNTN4' 'A' 'rs17194378' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'CSMD1' 'A' 'rs17070785' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'PLAGL1' 'C' 'rs2247408' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'PLAGL1' 'A' 'rs3819811' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'PTPRN2' 'C' 'rs221253' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' 'PRKCE' 'C' 'rs2278773' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['PERPHENAZINE' nan 'C' 'rs11774231' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['METFORMIN' 'SLC22A1' 'CC' 'rs622342' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'OTHER:GENETIC_VARIATION_AT_RS2289669' 'CAUTION_DOSE_ADJUST']
['ATAZANAVIR' 'ABCB1' 'AA + AG' 'rs1045642' 'DOSAGE' 'nan_DOSE' nan
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['ATAZANAVIR' 'SLCO1B1' 'TT' 'rs4149056' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['ATAZANAVIR' 'NR1I2' 'TT' 'rs2472677' 'DOSAGE' 'nan_DOSE' nan 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'VKORC1' 'T' 'rs9923231' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['CLOZAPINE' 'SLC6A4' 'T' 'rs25531' 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'T' 'rs113993959' 'EFFICACY' 'nan_RESPONSE' nan
 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'T' 'rs75039782' 'EFFICACY' 'nan_RESPONSE' nan
 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'A' 'rs77010898' 'EFFICACY' 'nan_RESPONSE' nan
 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ESTRONE_SULFATE' 'SLCO1B1' 'C' 'rs10841753' 'METABOLISM/PK'
 'DECREASED_nan' nan 'WOMEN' 'OTHER:BREAST_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1B' 'A' 'rs2018417' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1B' 'C' 'rs17033' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1B' 'G' 'rs1229985' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1A' 'A' 'rs931635' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1C' 'A' 'rs283416' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1C' 'A' 'rs283411' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1C' 'C' 'rs1662060' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'AA + AG' 'rs78655421' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH7' 'C' 'rs1154461' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1A' 'C' 'rs1229967' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1A' 'C' 'rs2276332' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['ETHANOL' 'ADH1A' 'C' 'rs1229976' 'TOXICITY, METABOLISM/PK'
 'nan_METABOLISM' nan nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL_THIOL_METABOLITE_H4' 'CYP2C19' 'A' 'rs4244285'
 'METABOLISM/PK' 'nan_EXPOSURE' nan nan nan 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'AA + AG' 'rs78655421' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'A' 'rs77010898' 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE'
 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'T' 'rs113993959' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'T' 'rs75039782' 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE'
 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'A' 'rs77010898' 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE'
 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['ATALUREN' 'CFTR' 'T' 'rs113993959' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'AA + AG' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, OXCARBAZEPINE' 'SCN1A' 'TT' 'rs3812718' 'EFFICACY'
 'nan_RESISTANCE' nan 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, OXCARBAZEPINE' 'SCN1A' 'TT' 'rs3812718' 'EFFICACY'
 'nan_RESISTANCE' nan 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, OXCARBAZEPINE' 'ABCC2' 'AG' 'rs2273697' 'EFFICACY'
 'nan_RESISTANCE' nan 'PEOPLE' 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['CYCLOPHOSPHAMIDE' 'CYP2B6' 'C' 'rs7254579' 'METABOLISM/PK'
 'nan_METABOLISM' nan 'PEOPLE' 'DISEASE:LUPUS_ERYTHEMATOSUS'
 'CAUTION_DOSE_ADJUST']
['DEFERASIROX' 'VDR' 'AA' 'rs7975232' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'CHILDREN' 'DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES'
 'CAUTION_DOSE_ADJUST']
['DEFERASIROX' 'VDR' 'G' 'rs2228570' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'CHILDREN' 'DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES'
 'CAUTION_DOSE_ADJUST']
['GEFITINIB' 'EGFR' 'G' 'rs121434568' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['ERLOTINIB' 'EGFR' 'G' 'rs121434568' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2A6' 'T' 'rs28399454' 'METABOLISM/PK' 'nan_METABOLISM'
 nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'T' 'rs3745274' 'METABOLISM/PK' 'nan_METABOLISM' nan
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'C' 'rs28399499' 'METABOLISM/PK' 'nan_METABOLISM'
 nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['VALPROIC_ACID' 'UGT2B7' 'TT' 'rs7439366' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs121908757' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs121909005' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121908755' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs397508453' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121909013' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs121909041' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs74503330' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs267606723' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs80282562' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs193922525' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['LUMACAFTOR' 'CFTR' 'AA' 'rs121909047' 'EFFICACY' 'nan_RESPONSE' nan nan
 nan 'CAUTION_DOSE_ADJUST']
['SORAFENIB' 'ABCG2' 'CT' 'rs2231137' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['SORAFENIB' 'ABCG2' 'GT' 'rs2231142' 'METABOLISM/PK' 'nan_CONCENTRATIONS'
 nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs78655421' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR, TEZACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE'
 nan 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs121908757' 'EFFICACY' 'nan_RESPONSE' nan
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C19' 'C' 'rs3814637' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' 'A' 'rs4917639' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'VKORC1' 'A' 'rs2359612' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLIC_ACID' 'ABCC2' 'T' 'rs717620' 'METABOLISM/PK' 'nan_EXPOSURE'
 nan 'PEOPLE' 'OTHER:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLIC_ACID' 'ABCC2' 'T' 'rs717620' 'METABOLISM/PK' 'nan_EXPOSURE'
 nan 'PEOPLE' 'OTHER:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC_ACID' 'SCN2A' 'A'
 'rs17183814' 'EFFICACY' 'nan_RESISTANCE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['RITONAVIR' 'ABCB1' 'AC + CC' 'rs2032582' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['RITONAVIR' 'NR1I2' 'AA + AG' 'rs6785049' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['FLUINDIONE' 'VKORC1' 'TT' 'rs9923231' 'METABOLISM/PK' 'nan_DOSE' nan
 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['BENAZEPRIL' 'AGT' 'GG' 'rs4762' 'EFFICACY' 'nan_RESPONSE' nan 'MEN'
 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['BENAZEPRIL' 'AGTR1' 'GG' 'rs2640543' 'EFFICACY' 'nan_RESPONSE' nan
 'WOMEN' 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['BENAZEPRIL' 'SPTA1' 'G' 'rs2106089' 'EFFICACY' 'nan_RESPONSE' nan 'MEN'
 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A7' 'C' 'rs2257401' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'C' 'rs776746' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'A' 'rs4646437' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'T' 'rs2242480' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'A' 'rs41303343' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'A' 'rs4646450' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'T' 'rs2740574' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'A' 'rs35599367' 'METABOLISM/PK'
 'nan_TROUGH_CONCENTRATION' nan 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['TRANDOLAPRIL, VERAPAMIL' 'PTPRD' 'T' 'rs4742610' 'EFFICACY'
 'nan_RESISTANCE' nan 'PEOPLE' 'DISEASE:HYPERTENSION'
 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE' 'EPHX1' 'CG' 'rs3738046' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE' 'EPHX1' 'AG + GG' 'rs2234922' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['WARFARIN' nan 'T' 'rs12772169' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_RESPONSE' nan
 'CHILDREN' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['CEFTRIAXONE' 'ABCG2' 'TT' 'rs13120400' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE'
 'DISEASE:CENTRAL_NERVOUS_SYSTEM_INFECTIOUS_DISORDER'
 'CAUTION_DOSE_ADJUST']
['CARBOPLATIN, LONAFARNIB, PACLITAXEL' 'FNTB' 'GG' 'rs11623866' 'EFFICACY'
 'nan_RESPONSE' nan 'WOMEN' 'DISEASE:OVARIAN_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'GT + TT' 'rs3745274' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'G' 'rs35303484' 'METABOLISM/PK'
 'nan_CONCENTRATIONS' nan 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'ABCB1' 'C' 'rs3842' 'METABOLISM/PK' 'nan_CONCENTRATIONS' nan
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['BENAZEPRIL' 'AGT' 'GG' 'rs7079' 'EFFICACY' 'nan_RESPONSE' nan 'WOMEN'
 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'MECP2' 'A' 'rs1734791'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'MECP2' 'A' 'rs1734787'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'MECP2' 'A' 'rs17435' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'T' 'rs5906072' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'G' 'rs12613732'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'C' 'rs5009910'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'C' 'rs6752303'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'C' 'rs10209881'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'A' 'rs12999804'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'C' 'rs5934731' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'C' 'rs715171' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'C' 'rs4932551' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'T' 'rs7170769' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' nan 'C' 'rs6458232' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, FLUOROURACIL, MITOXANTRONE' 'GALNT14' 'C' 'rs7608731'
 'EFFICACY' 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'CAUTION_DOSE_ADJUST']
['ALLOPURINOL, FEBUXOSTAT' 'AOX1' 'G' 'rs3731722' 'DOSAGE' 'nan_DOSE' nan
 'PEOPLE' 'DISEASE:GOUT' 'CAUTION_DOSE_ADJUST']
['ALLOPURINOL, FEBUXOSTAT' 'AOX1' 'T' 'rs11678615' 'DOSAGE' 'nan_DOSE' nan
 'PEOPLE' 'DISEASE:GOUT' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP4F2' 'T' 'rs2108622' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE' 'ITPA' 'A' 'rs1127354' 'METABOLISM/PK' 'nan_METABOLISM'
 nan 'PEOPLE' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['TRASTUZUMAB' 'ERBB2' 'G' 'rs1136201' 'TOXICITY' 'nan_RESPONSE' nan nan
 nan 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE' 'TPMT' 'C' 'rs1142345' 'EFFICACY' 'nan_EXPOSURE' nan
 'CHILDREN' 'DISEASE:LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['FLUTICASONE/SALMETEROL' 'CHRM2' 'A' 'rs8191992' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:ASTHMA' 'CAUTION_DOSE_ADJUST']
['FLUTICASONE/SALMETEROL' 'CHRM2' 'A' 'rs6962027' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:ASTHMA' 'CAUTION_DOSE_ADJUST']
['FLUTICASONE/SALMETEROL' 'CHRM2' 'A' 'rs6962027' 'EFFICACY'
 'nan_RESPONSE' nan 'PEOPLE' 'DISEASE:ASTHMA' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'VKORC1' 'CT + TT' 'rs9923231' 'DOSAGE' 'nan_DOSE' nan nan nan
 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'del' 'rs113993960' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_PROTEIN_STABILITY'
 nan nan 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121909047' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs113993958' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs397508288' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs397508537' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs78769542' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs1800111' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121909020' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs397508442' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs74551128' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs186045772' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs397508256' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs368505753' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs202179988' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121909019' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121908753' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs77834169' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs121908752' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs77932196' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs141033578' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs121909011' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs77409459' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs397508510' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs397508139' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs397508435' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs121908751' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs397508328' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs11971167' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs75541969' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs34911792' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'G' 'rs150212784' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs397508759' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs78655421' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs115545701' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'C' 'rs397508513' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'T' 'rs1800100' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['ANASTROZOLE, EXEMESTANE, LETROZOLE' 'CYP19A1' 'AG' 'rs6493497' 'OTHER'
 'nan_ACTIVITY' nan nan 'CYP19A1' 'CAUTION_DOSE_ADJUST']
['ANASTROZOLE, EXEMESTANE, LETROZOLE' 'CYP19A1' 'CT' 'rs7176005' 'OTHER'
 'nan_ACTIVITY' nan nan 'CYP19A1' 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'CT' 'rs118192172' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'GT' 'rs193922772' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'CT' 'rs118192175' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'AG' 'rs118192176' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'CT' 'rs28933397' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE, HALOTHANE' 'RYR1' 'CT' 'rs193922747' 'OTHER' 'nan_SENSITIVITY'
 nan nan nan 'CAUTION_DOSE_ADJUST']
['IVACAFTOR' 'CFTR' 'A' 'rs75527207' 'EFFICACY' 'nan_ACTIVITY' nan nan
 'CFTR' 'CAUTION_DOSE_ADJUST']
['OXAZEPAM' 'UGT1A1' 'G' 'rs4124874' 'OTHER' 'nan_GLUCURONIDATION' nan nan
 nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'T' 'rs2740574' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN, SIMEPREVIR' 'IFNL3, IFNL4' 'TT'
 'rs8099917' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_AUC24' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*4/*4' 'CYP2D6*4' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NORTRIPTYLINE' 'UST' 'A' 'rs2500535' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:IMPROVEMENT_OF_DEPRESSION_SYMPTOMS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A4' 'G' 'rs1851426' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'nan_nan' 'EFFICACY:TIME_TO_THERAPEUTIC_INR' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*6/*6' 'CYP2D6*6' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*5/*5' 'CYP2D6*5' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OXAZEPAM' 'UGT2B15' 'AA' 'rs1902023' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES' nan nan
 'CAUTION_DOSE_ADJUST']
['OXAZEPAM' 'UGT2B15' 'AA' 'rs1902023' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:OXAZEPAM_ORAL_CLEARANCE' nan nan 'CAUTION_DOSE_ADJUST']
['NITROUS_OXIDE' 'MTHFR' 'AA' 'rs1801133' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS' 'PEOPLE'
 'OTHER:SURGERY' 'CAUTION_SIDE_EFFECT']
['BUSULFAN' 'CYP2B6' '*1/*1 + *1/*5 + *1/*9'
 'CYP2B6*1, CYP2B6*5, CYP2B6*9' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'CHILDREN'
 'DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUVOXAMINE' 'CYP2D6' '*1/*10 + *1/*5 + *10/*10 + *5/*10'
 'CYP2D6*1, CYP2D6*5, CYP2D6*10' 'METABOLISM/PK' 'nan_nan'
 'PK:DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY' 'PEOPLE'
 nan 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B' 'IDO1' 'CC' 'rs9657182'
 'TOXICITY' 'INCREASED_nan' 'SIDE_EFFECT:DEPRESSION' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION' 'CAUTION_SIDE_EFFECT']
['NITROUS_OXIDE' 'MTHFR' 'GG' 'rs1801131' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS' 'PEOPLE'
 'OTHER:SURGERY' 'CAUTION_SIDE_EFFECT']
['OMEPRAZOLE' 'CYP2C19' 'TT' 'rs11188072' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan' 'PK:AUC' 'PEOPLE' 'OTHER:NO_DISEASE'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CARBOPLATIN, PACLITAXEL' 'ABCB1' 'AA' 'rs2032582' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:OVARIAN_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*1/*1' 'CYP2D6*1, CYP2D6*10' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTIPSYCHOTICS' 'CYP2D6' '*10' 'CYP2D6*1, CYP2D6*10' 'TOXICITY'
 'nan_RISK' 'SIDE_EFFECT:TARDIVE_DYSKINESIA' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*10/*10' 'CYP2D6*1, CYP2D6*10' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ASPIRIN, CILOSTAZOL, CLOPIDOGREL' 'CYP2C19' '*2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'EFFICACY:MAXIMAL_PLATELET_AGGREGATION' nan
 'OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.)'
 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' 'A' 'rs4986893' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*4/*4 + *1/*4' 'CYP2D6*1, CYP2D6*4' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OMEPRAZOLE' 'CYP2C19' 'TT' 'rs12248560' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan' 'PK:AUC' 'PEOPLE' 'OTHER:NO_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' 'TT' 'rs11188072' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:CONCENTRATION/DOSE_RATIO' 'PEOPLE'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:CONCENTRATION/DOSE_RATIO' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TENOFOVIR' 'ABCC10' 'C' 'rs2125739' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_SIDE_EFFECT']
['TACROLIMUS' 'CYP3A5' '*1/*3 + *3/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:BLOOD_CONCENTRATION/DOSAGE_RATIO'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:CONCENTRATION/DOSE_RATIO' 'CHILDREN'
 'OTHER:HEART_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'A' 'rs2687116' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' 'A' 'rs4244285' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['NAN' 'IFNL4' 'TT/TT' 'rs11322783' 'OTHER' 'INCREASED_nan'
 'OTHER:SPONTANEOUS_HCV_CLEARANCE' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION' 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE' 'TPMT' '*1/*2 + *1/*3A + *1/*3C'
 'TPMT*1, TPMT*2, TPMT*3A, TPMT*3C' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:6-MMPN_LEVELS' 'CHILDREN' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA'
 'CAUTION_DOSE_ADJUST']
['AZATHIOPRINE' 'TPMT' '*1/*3A + *1/*3B + *1/*3C'
 'TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C' 'TOXICITY' 'DECREASED_nan'
 'SIDE_EFFECT:HEMATOLOGICAL_INDICES' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*10/*10' 'CYP2D6*10'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'SIDE_EFFECT:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOSPORINE' 'TPMT' '*1/*3A + *1/*3B + *1/*3C'
 'TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C' 'TOXICITY' 'INCREASED_nan'
 'PK:PLASMA_LEVELS' 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION'
 'CAUTION_SIDE_EFFECT']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT'
 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CISPLATIN, PEMETREXED' 'MTHFR' 'GG + GT' 'rs1801131' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:STOMACH_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ESCITALOPRAM' 'CYP2C19' 'TT' 'rs12248560' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*10/*5 + *10/*10 + *10/*41'
 'CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'SIDE_EFFECT:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TENOFOVIR' 'ABCC10' 'G' 'rs9349256' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION' nan nan 'CAUTION_SIDE_EFFECT']
['FLUOROURACIL' 'CYP2A6' '*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9'
 'CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE' 'PEOPLE'
 'DISEASE:NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TEGAFUR/GIMERACIL/OTERACIL' 'CYP2A6' '*4 + *7 + *9 + *10'
 'CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:STOMACH_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL, ROSUVASTATIN' 'CYP2C19' '*2 + *3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'OTHER' 'INCREASED_nan'
 'OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES' nan
 'OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION'
 'CAUTION_DOSE_ADJUST']
['TEGAFUR' 'CYP2A6' '*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9'
 'CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE' 'PEOPLE'
 'DISEASE:NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'OTHER'
 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS' nan
 'OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION'
 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, PLATINUM' 'C18orf56, TYMS'
 '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3'
 'rs45445694' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ONDANSETRON' 'SLC6A4'
 'HTTLPR long form (L allele)/HTTLPR long form (L allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'INCREASED_nan'
 'OTHER:PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY'
 'PEOPLE' 'DISEASE:ALCOHOL_ABUSE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOROURACIL' 'TYMS' '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2' 'rs45445694'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:STOMACH_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOPHOSPHAMIDE' 'CYP2B6' '*5/*6' 'CYP2B6*1, CYP2B6*5, CYP2B6*6'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METHOTREXATE' 'SLC19A1' 'T' 'rs1051266' 'EFFICACY' 'nan_nan'
 'EFFICACY:WORSE_PROGNOSES' 'PEOPLE'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*11' 'CYP2C9*1, CYP2C9*11' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)' 'HEALTHY'
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['GEMCITABINE, PLATINUM_COMPOUNDS' 'RRM1' 'C' 'rs1042927' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL_PROBABILITY' 'PEOPLE'
 'DISEASE:MESOTHELIOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CAPECITABINE, PACLITAXEL' 'TYMS' 'TTAAAGTTA/TTAAAGTTA' 'rs11280056'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:STOMACH_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN' 'SHMT1' 'A'
 'rs1979277' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)'
 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MERCAPTOPURINE, METHOTREXATE' 'TPMT' 'C' 'rs1142345' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:GI_TOXICITY' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['NAN' 'CYP3A5, ZSCAN25' 'CC' 'rs776746' 'NAN' 'nan_nan'
 'SIDE_EFFECT:DRUG_TOXICITY' nan nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'C' 'rs776746' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['PACLITAXEL' 'ABCB1' 'AA' 'rs2032582' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:CHANCE_OF_POSITIVE_RESPONSE_TO_PACLITAXEL' 'PEOPLE'
 'DISEASE:OVARIAN_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MERCAPTOPURINE' 'NUDT15' '*1/*2 + *1/*3 + *1/*6 + *2/*2'
 'NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:NEUTROPENIA' 'CHILDREN' 'OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA'
 'CAUTION_SIDE_EFFECT']
['OMEPRAZOLE' 'CYP2C19' '*1/*1 + *1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'DECREASED_nan'
 'DISEASE:GASTRIC_PH' 'PEOPLE' 'DISEASE:HELICOBACTER_INFECTIONS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METHOTREXATE' 'SLCO1B1' 'C' 'rs4149056' 'OTHER, METABOLISM/PK'
 'DECREASED_nan' 'PK:CLEARANCE' 'PEOPLE'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['ASPARAGINASE' 'HLA-DRB1' '*07:01' 'HLA-DRB1*07:01' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:DRUG_HYPERSENSITIVITY' 'CHILDREN'
 'OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['REPAGLINIDE' 'CYP2C8' '*3' 'CYP2C8*3' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:REPAGLINIDE_AUC' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A7' 'C' 'rs2257401' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A4' 'G' 'rs4646437' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['ALLOPURINOL' 'HLA-B' '*58:01' 'HLA-B*58:01' 'TOXICITY' 'nan_RISK'
 'DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME'
 nan nan 'CAUTION_DOSE_ADJUST']
['CISPLATIN, IRINOTECAN' 'UGT1A1' 'AA' 'rs4148323' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTHRACYCLINES_AND_RELATED_SUBSTANCES, TAMOXIFEN' 'CYP2D6' '*4/*4'
 'CYP2D6*1, CYP2D6*4' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A4' 'C' 'rs6956344' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CISPLATIN, IRINOTECAN' 'UGT1A1' 'AA' 'rs4148323' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PACLITAXEL' 'ABCB1' 'AG' 'rs1045642' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:DISEASE_CONTROL_RATE_AND_LOWER_OVERALL_SURVIVAL_RATE' 'PEOPLE'
 'OTHER:METASTATIC_BREAST_CANCER' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*2' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*2' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:POST-TREATMENT_ADP-STIMULATED_PLATELET_AGGREGATION' 'HEALTHY'
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6'
 '*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10X2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2/*2' 'CYP2C19*2' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_BLOOD_LEVELS' 'PEOPLE'
 'OTHER:LUNG_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATION' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:TROUGH_CONCENTRATION' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'C' 'rs2242480' 'METABOLISM/PK' 'nan_nan'
 'PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)' nan nan
 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A5' '*1/*1' 'CYP3A5*1, CYP3A5*3' 'OTHER'
 'INCREASED_nan' 'OTHER:CREATININE_CLEARANCE' 'CHILDREN'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['FLECAINIDE' 'CYP2D6' '*4 + *5 + *10 + *21 + *36'
 'CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS'
 nan nan 'CAUTION_DOSE_ADJUST']
['NORTRIPTYLINE' 'CYP2D6' '*3' 'CYP2D6*1, CYP2D6*3' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['FLECAINIDE' 'CYP2D6' '*5/*36 + *10/*10 + *10/*36 + *21/*36'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6'
 '*4/*4 + *4/*41 + *1/*5 + *2/*5'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:TROUGH_CONCENTRATIONS' 'CHILDREN'
 'OTHER:HEART_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['NORTRIPTYLINE' 'CYP2D6' '*10' 'CYP2D6*1, CYP2D6*2, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['RHODAMINE_123' 'ABCB1' 'GG' 'rs1045642' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS' nan nan
 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE, THIOGUANINE' 'TPMT' '*1/*3A' 'TPMT*1, TPMT*3A'
 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:THROMBOCYTOPENIA' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['CELECOXIB' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PAIN' 'CHILDREN' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*3/*4 + *4/*6'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT'
 'PEOPLE' 'DISEASE:DEPRESSION' 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*4 + *5' 'CYP2D6*1, CYP2D6*4, CYP2D6*5'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE, _MIRTAZAPINE_S(+)/R(-)_RATIOS_AND_S(+)-N-DESMETHYLMIRTAZAPINE'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['CYCLOSPORINE' 'CYP3A4' '*1/*1 + *1/*18' 'CYP3A4*1, CYP3A4*18'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS'
 'CHILDREN' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*2 + *1/*3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE' nan 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROTHROMBIN_TIME_(PT)_AT_INDUCTION' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ROSIGLITAZONE' 'CYP2C8' '*3' 'CYP2C8*1, CYP2C8*3' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:WEIGHT_GAIN' 'PEOPLE'
 'DISEASE:DIABETES_MELLITUS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ASPIRIN, CILOSTAZOL, CLOPIDOGREL' 'CYP2C19' '*2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan
 'OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.)'
 'CAUTION_DOSE_ADJUST']
['PACLITAXEL, PLATINUM_COMPOUNDS' 'NAT2' 'AA' 'rs1799931' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:LUNG_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CAFFEINE' 'CYP1A2' nan 'CYP1A2 LOW ACTIVITY' 'OTHER' 'INCREASED_nan'
 'OTHER:INTAKE' 'WOMEN' 'DISEASE:PREGNANCY' 'CAUTION_DOSE_ADJUST']
['NAN' 'HMGCR' 'AA' 'rs3846662' 'OTHER' 'DECREASED_nan'
 'OTHER:HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT'
 nan nan 'CAUTION_DOSE_ADJUST']
['ATAZANAVIR, RITONAVIR' 'UGT1A1' '*28' 'UGT1A1*28' 'METABOLISM/PK'
 'nan_nan' 'DISEASE:HYPERBILIRUBINEMIA' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*1, CYP2C9*2' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY'
 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY'
 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['NAN' 'DHFR' 'del/del' 'rs70991108' 'OTHER' 'INCREASED_nan'
 'OTHER:SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS' nan nan
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, IRINOTECAN' 'UGT1A1' 'AA' 'rs4148323' 'TOXICITY'
 'INCREASED_nan' 'DISEASE:NEUTROPENIA' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'CAUTION_SIDE_EFFECT']
['NICOTINE' 'CYP2A6' '*20 + *26 + *24+ *9 + *27 + *17'
 'CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27'
 'OTHER, METABOLISM/PK' 'DECREASED_nan' 'PK:METABOLISM' nan nan
 'CAUTION_DOSE_ADJUST']
['INTERFERON_BETA-1A, INTERFERON_BETA-1B' 'HLA-DQA1' 'G' 'rs9272105'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:ANTI-IFN-BETA_ANTIBODIES' 'PEOPLE'
 'DISEASE:MULTIPLE_SCLEROSIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['REPAGLINIDE' 'SLCO1B1' '*37/*37'
 'SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['EGFR_INHIBITORS' 'EGFR' 'A' 'rs2227983' 'EFFICACY' 'nan_nan'
 'EFFICACY:CYTOTOXICITY' nan nan 'CAUTION_DOSE_ADJUST']
['INTERFERON_BETA-1A, INTERFERON_BETA-1B' nan 'G' 'rs4961252' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ANTI-IFN-BETA_ANTIBODIES' 'PEOPLE'
 'DISEASE:MULTIPLE_SCLEROSIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METHOTREXATE' 'C18orf56, TYMS'
 '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3'
 'rs45445694' 'EFFICACY' 'DECREASED_nan' 'EFFICACY:EVENT_FREE_SURVIVAL'
 'PEOPLE' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' nan
 'CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:HEMORRHAGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NORTRIPTYLINE' 'CYP2D6' '*3' 'CYP2D6*1, CYP2D6*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:_APPARENT_TERMINAL_ELIMINATION_HALF-LIFE' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['ATAZANAVIR' 'CYP3A5' '*1/*3 + *1/*1' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR'
 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['EGFR_INHIBITORS' 'EGFR' 'T' 'rs712829' 'TOXICITY' 'nan_nan'
 'EFFICACY:CYTOTOXICITY' nan nan 'CAUTION_DOSE_ADJUST']
['AZATHIOPRINE' 'TPMT' '*1/*1' 'TPMT*1, TPMT*2, TPMT*3A' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:TREATMENT_DURATION' 'PEOPLE'
 'DISEASE:RHEUMATIC_DISEASES' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ATORVASTATIN, PRAVASTATIN' 'APOE' 'CC + CT' 'rs429358' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP)' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' '*4/*5' 'CYP2D6*4, CYP2D6*5' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*4/*7' 'CYP2D6*4, CYP2D6*7' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TRAMADOL' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER'
 'EFFICACY, METABOLISM/PK' 'DECREASED_nan'
 'EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL' nan
 nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*4/*6' 'CYP2D6*4, CYP2D6*6' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OMEPRAZOLE' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:INTRAGASTRIC_PH' 'PEOPLE' 'DISEASE:ULCER'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NORTRIPTYLINE' 'CYP2D6' '*5' 'CYP2D6*1, CYP2D6*5' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['TICAGRELOR' 'CYP3A4' '*1/*22' 'CYP3A4*1, CYP3A4*22' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_AGGREGATION_INHIBITION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' '*4/*11' 'CYP2D6*4, CYP2D6*11' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOSPORINE' 'ABCB1' 'AA' 'rs1128503' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:TROUGH_BLOOD_CONCENTRATION' 'PEOPLE'
 'DISEASE:MYASTHENIA_GRAVIS' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*3/*4' 'CYP2D6*3, CYP2D6*4' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NORTRIPTYLINE' 'CYP2D6' '*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*3/*5' 'CYP2D6*3, CYP2D6*5' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOSPORINE' 'ABCB1' 'AA' 'rs2032582' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:TROUGH_BLOOD_CONCENTRATION' 'PEOPLE'
 'DISEASE:MYASTHENIA_GRAVIS' 'CAUTION_DOSE_ADJUST']
['SERTRALINE' 'CYP2C19' '*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3'
 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'DOSAGE, EFFICACY' 'INCREASED_nan'
 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['FLUVOXAMINE' 'CYP2D6' '*10/*10 + *5/*10' 'CYP2D6*1, CYP2D6*5, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:FLUVOXAMINE_PLASMA_CONCENTRATIONS'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*2/*2 + *2/*4'
 'CYP2C19*1, CYP2C19*2, CYP2C19*4' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24))' nan nan
 'CAUTION_DOSE_ADJUST']
['ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE' 'CYP2D6' '*1/*1' 'CYP2D6*1'
 'EFFICACY, METABOLISM/PK' 'nan_nan' 'PK:INHIBITION_OF_METABOLISM'
 'PEOPLE' 'DISEASE:BACK_PAIN' 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*2/*2' 'CYP2C19*1, CYP2C19*2' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE' nan nan
 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*1/*17' 'CYP2C19*1, CYP2C19*17' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE, R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['AZATHIOPRINE' 'TPMT' '*1/*3A + *1/*3C' 'TPMT*1, TPMT*3A, TPMT*3C'
 'TOXICITY' 'DECREASED_nan' 'SIDE_EFFECT:LEUKOCYTES_AND_NEUTROPHILS'
 'PEOPLE' 'DISEASE:HEART_TRANSPLANTATION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*4/*4 + *4/*5 + *10/*41 + *4/*41'
 'CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['DOCETAXEL' 'VEGFA' 'del/del' 'rs144854329' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN' nan nan
 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'SLC6A4' 'L allele-rs25531T/L allele-rs25531T'
 'SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T'
 'TOXICITY' 'DECREASED_nan' 'SIDE_EFFECT:ADVERSE_EFFECT_BURDEN' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CARBOPLATIN, CISPLATIN' 'DPYD' 'Reference' 'DPYD REFERENCE' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' 'TT' 'rs776746' 'DOSAGE, METABOLISM/PK' 'nan_nan'
 'OTHER:HIGHER_STABLE_DOSE_LEVELS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5'
 'CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' 'A' 'rs4244285' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:CLOPI-H4_CONCENTRATIONS_AFTER_300_OR_900_MG_CLOPIDOGREL_LOADING_DOSE'
 'MEN' 'DISEASE:MYOCARDIAL_INFARCTION' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ATORVASTATIN, PRAVASTATIN' 'APOE' 'CT + TT' 'rs7412' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ANTICHOLINERGIC_AGENTS' 'CYP2D6' nan 'CYP2D6 POOR METABOLIZER'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:SERUM_ANTICHOLINERGIC_ACTIVITY' nan
 nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:FORMATION_OF_METABOLITES' nan
 'OTHER:HUMAN_LIVER_MICROSOMES' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:PLASMA_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN' 'UGT1A1' '*6'
 'UGT1A1*6' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'G6PD' 'T' 'rs1050828' 'NAN' 'INCREASED_nan'
 'OTHER:PROTECTION_AGAINST_SEVERE_MALARIA' nan nan 'CAUTION_DOSE_ADJUST']
['PRAVASTATIN' 'SLCO1B1' '*15/*15' 'SLCO1B1*15, SLCO1B1*37'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ACENOCOUMAROL' 'CYP2C9' '*1/*3 + *3/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_IN_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA_BLOCKING_AGENTS, CALCIUM_CHANNEL_BLOCKERS'
 'ACE'
 'ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC'
 'rs1799752' 'OTHER' 'DECREASED_nan' 'OTHER:USE' 'PEOPLE'
 'OTHER:CHRONIC_MIGRAINE' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA_BLOCKING_AGENTS, CALCIUM_CHANNEL_BLOCKERS'
 'ACE'
 'ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC'
 'rs1799752' 'OTHER' 'DECREASED_nan' 'OTHER:USE' 'PEOPLE'
 'DISEASE:MIGRAINE_WITH_AURA' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:C/D_RATIO' 'PEOPLE' 'DISEASE:LIVER_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['PHENPROCOUMON' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR'
 'IFNL4' 'TT/TT' 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ROSIGLITAZONE' 'PLIN1' 'CT + TT' 'rs894160' 'TOXICITY' 'DECREASED_nan'
 'SIDE_EFFECT:WEIGHT_GAIN' 'PEOPLE' 'OTHER:DIABETES_MELLITUS_T2'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CITALOPRAM' 'CYP2D6' '*1/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:AUC_OF_CITALOPRAM' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2 + *3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PRASUGREL' 'PEAR1' 'AA' 'rs822442' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT'
 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOROURACIL' 'DPYD' nan 'DPYD DEFICIENCY' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:DRUG_TOXICITY' 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['RISPERIDONE' 'CYP2D6' '*4/*4 + *4/*5 + *4/*6'
 'CYP2D6*4, CYP2D6*5, CYP2D6*6' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:REDUCTION_IN_PSYCHOTIC_SYMPTOMS' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BOSENTAN' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:BOSENTAN_METABOLISM_IN_VITRO' nan nan
 'CAUTION_DOSE_ADJUST']
['BOSENTAN' 'CYP2C9' '*2' 'CYP2C9*1, CYP2C9*2' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:BOSENTAN_METABOLISM_IN_VITRO' nan nan
 'CAUTION_DOSE_ADJUST']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'CT' 'rs3918290' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:DRUG_TOXICITY' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_SIDE_EFFECT']
['FOLFIRI' 'UGT1A1' '*1/*28 + *28/*28' 'UGT1A1*1, UGT1A1*28' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:NEUTROPENIA' 'PEOPLE'
 'OTHER:COLORECTAL_NEOPLASMS' 'CAUTION_SIDE_EFFECT']
['ATORVASTATIN' 'TNF' 'GG' 'rs1800629' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_IN_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR' 'IFNL4' 'TT/TT'
 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR), PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY)'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUVOXAMINE, PAROXETINE' 'SLC6A4' 'HTTLPR long form (L allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METHOTREXATE' 'SLCO1B1' 'T' 'rs11045879' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:CLEARANCE' 'PEOPLE'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_LEVELS' 'PEOPLE'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:CONCENTRATION/DOSE_RATIO' 'PEOPLE'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:C/D_RATIO' 'PEOPLE' 'DISEASE:LIVER_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_REACTIVITY_AFTER_9MONTH_OF_TREATMENT'
 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A5' '*1/*3 + *3/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:BLOOD_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['NAN' 'KCNE1' 'T' 'rs727957' 'OTHER' 'INCREASED_nan' 'OTHER:QT_INTERVAL'
 nan nan 'CAUTION_DOSE_ADJUST']
['HYDROCHLOROTHIAZIDE' 'ACE' 'del/del' 'rs1799752' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:REDUCTION_IN_SYSTOLIC_BLOOD_PRESSURE' 'PEOPLE'
 'DISEASE:ESSENTIAL_HYPERTENSION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['RALOXIFENE' 'UGT1A1' '*28/*28' 'UGT1A1*1, UGT1A1*28' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:BONE_MINERAL_DENSITY' 'WOMEN'
 'DISEASE:OSTEOPOROSIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL3' 'CC'
 'rs12979860' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS'
 'PEOPLE' 'DISEASE:HEPATITIS_C_VIRUS_INFECTION' 'CAUTION_DOSE_ADJUST']
['PRASUGREL' 'PEAR1' 'TT' 'rs3737224' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PRASUGREL' 'PEAR1' 'TT' 'rs41273215' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PAROXETINE' 'SLC6A4' 'HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:TIME_TO_IMPROVE_(BASED_ON_MEAN_REDUCTIONS_FROM_BASELINE_IN_HRSD)'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TRAMADOL' 'CYP2D6' '*10/*10' 'CYP2D6*1, CYP2D6*10' 'DOSAGE' 'nan_nan'
 'OTHER:SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY'
 nan nan 'CAUTION_DOSE_ADJUST']
['PRASUGREL' 'PEAR1' 'CC' 'rs822441' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-RESPONSE' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY'
 nan nan 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-RESPONSE' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-RESPONSE' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:IMPROVED_SECOND_TREATMENT_SWITCH_RESPONSE'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-REMISSION' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-RESPONSE' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_DOSE_ADJUST']
['ETRAVIRINE' 'CYP2C19' 'AA + AG' 'rs4244285' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:ETRAVIRINE_CLEARANCE' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'ERCC1' 'A' 'rs3212986' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:NEOPLASM_OF_ESOPHAGUS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ROSUVASTATIN' 'ABCG2' 'T' 'rs2231142' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDL-C)_LEVEL, IN_A_GENE-DOSE-DEPENDENT_MANNER,'
 'PEOPLE' 'DISEASE:HYPERCHOLESTEROLEMIA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOXETINE, PAROXETINE' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METFORMIN' 'SLC22A1' 'GAT/del' 'rs72552763' 'OTHER, METABOLISM/PK'
 'DECREASED_nan' 'EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION'
 'PEOPLE' 'DISEASE:DIABETES_MELLITUS_T2' 'CAUTION_DOSE_ADJUST']
['PHENAZEPAM' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:DRUG_TOXICITY' 'MEN'
 'OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS' 'CAUTION_SIDE_EFFECT']
['METHOTREXATE' 'C18orf56, TYMS'
 '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3'
 'rs45445694' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION_FREE_SURVIVAL' 'CHILDREN'
 'OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['FLUOROURACIL' 'DPYD' nan 'DPYD DEFICIENCY' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:DRUG_TOXICITY' 'PEOPLE' 'DISEASE:NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP3A4' '*22' 'CYP3A4*1, CYP3A4*22' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:HOT_FLASHES' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ETHANOL' 'OPRM1' 'G' 'rs1799971' 'NAN' 'INCREASED_nan'
 'OTHER:ALCOHOL_RESPONSE, CONSUMPTION, AND_PREFERENCE' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2 + *3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['VENLAFAXINE' 'CYP2D6' '*4/*4' 'CYP2D6*4' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:VENLAFAXINE_LEVELS' 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'CAUTION_DOSE_ADJUST']
['EXEMESTANE' nan 'AA' 'rs934635' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2 + *3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:CORONARY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PRASUGREL' 'PEAR1' 'AA' 'rs12407843' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PRASUGREL' 'PEAR1' 'AA' 'rs77235035' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['VENLAFAXINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:VENLAFAXINE_LEVELS' 'PEOPLE'
 'DISEASE:OBSESSIVE_COMPULSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['VENLAFAXINE' 'CYP2D6' '*1/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:VENLAFAXINE_LEVELS' 'PEOPLE'
 'DISEASE:OBSESSIVE_COMPULSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*17/*17 + *1/*17' 'CYP2C19*1, CYP2C19*17'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:PLATELET_AGGREGATION_INHIBITION'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['IRINOTECAN' 'UGT1A1' '*6 + *28' 'UGT1A1*6, UGT1A1*28' 'TOXICITY'
 'nan_RISK' 'DISEASE:NEUTROPENIA' 'PEOPLE' 'DISEASE:NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:CMAX_AND_AUC_OF_THIOL_METABOLITE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['FLUTICASONE_PROPIONATE' 'CD14, TMCO6' 'AA' 'rs2569190' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PC20' 'CHILDREN' 'DISEASE:ASTHMA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE_REQUIREMENT' nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17' 'EFFICACY' 'nan_nan'
 'EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*2/*2 + *2/*3 + *3/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17' 'EFFICACY' 'nan_nan'
 'EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['METHOTREXATE' 'ATIC' 'GG' 'rs2372536' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN' 'PEOPLE'
 'DISEASE:RHEUMATOID_ARTHRITIS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['DOXEPIN' 'CYP2D6' '*4/*4' 'CYP2D6*4' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'CYP2D6' '*1/*3 + *1/*4' 'CYP2D6*1, CYP2D6*3, CYP2D6*4'
 'TOXICITY' 'INCREASED_nan' 'DISEASE:WEIGHT_GAIN' 'MEN'
 'DISEASE:SCHIZOPHRENIA' 'CAUTION_SIDE_EFFECT']
['EXEMESTANE' nan 'AA' 'rs934635' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_MUSCULOSKELETAL_ADVERSE_EVENTS_(MSAES)_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['DESIPRAMINE' 'CYP2D6' '*10/*10 + *5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M))' 'CHILDREN'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX))' 'CHILDREN'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*1/*4 + *4/*4'
 'CYP2D6*1, CYP2D6*4' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['IMIPRAMINE' 'CYP2C19' '*1/*17 + *17/*17' 'CYP2C19*1, CYP2C19*17'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS'
 'PEOPLE' 'DISEASE:DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PRIMAQUINE' 'G6PD' nan 'G6PD DEFICIENCY' 'OTHER' 'INCREASED_nan'
 'OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS' nan nan 'CAUTION_DOSE_ADJUST']
['SULFANILAMIDE' 'G6PD' nan 'G6PD DEFICIENCY' 'OTHER' 'INCREASED_nan'
 'OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS' nan nan 'CAUTION_DOSE_ADJUST']
['CHLORAMPHENICOL' 'G6PD' nan 'G6PD DEFICIENCY' 'OTHER' 'INCREASED_nan'
 'OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS' nan nan 'CAUTION_DOSE_ADJUST']
['CODEINE, MORPHINE, TRAMADOL' 'UGT2B7' 'A' 'rs73823859' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PAIN' 'CHILDREN' 'OTHER:SICKLE_CELL_ANEMIA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*8' 'CYP2C9*1, CYP2C9*8' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN'
 nan nan 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'ERCC2' 'G' 'rs13181' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:NEOPLASM_OF_ESOPHAGUS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PAROXETINE' 'SLC6A4'
 'HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T'
 'SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T'
 'TOXICITY' 'INCREASED_nan' 'SIDE_EFFECT:BLEEDING_TIME' 'PEOPLE'
 'DISEASE:MOOD_DISORDER' 'CAUTION_SIDE_EFFECT']
['ACE_INHIBITORS, PLAIN' 'ACE' 'del' 'rs1799752' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE'
 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE' 'CAUTION_SIDE_EFFECT']
['PACLITAXEL' 'CYP1B1' 'GG' 'rs1056836' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['DOCETAXEL' 'CYP1B1' 'CC' 'rs1056836' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:PROSTATIC_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP2C9' '*8' 'CYP2C9*1, CYP2C9*8' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan'
 'PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*1/*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['HYDROCHLOROTHIAZIDE' 'ACE'
 'ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC'
 'rs1799752' 'OTHER' 'INCREASED_nan'
 'OTHER:HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION' 'MEN'
 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['ENALAPRIL' 'ACE' 'del/del' 'rs1799752' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BONE_MINERAL_DENSITY_RESPONSE' 'WOMEN' 'DISEASE:HYPERTENSION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PAROXETINE' 'CYP2D6' '*1/*1xN' 'CYP2D6*1, CYP2D6*1XN' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:PAROXETINE_SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['RITONAVIR' 'APOC3' 'G' 'rs5128' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:TRIGLYCERIDE_LEVELS' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_SIDE_EFFECT']
['EFAVIRENZ' 'CYP2B6' 'T' 'rs3745274' 'TOXICITY, METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATION' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_SIDE_EFFECT']
['EFAVIRENZ' 'CYP2B6' '*1/*18' 'CYP2B6*1, CYP2B6*18' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_EFAVIRENZ_LEVELS' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['METHADONE' 'CYP2B6' '*6/*6' 'CYP2B6*1, CYP2B6*6' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:TROUGH_(_R_, S_)-METHADONE_PLASMA_CONCENTRATIONS' nan
 nan 'CAUTION_DOSE_ADJUST']
['MITOXANTRONE' 'ABCB1' 'AA' 'rs2032582' 'OTHER' 'INCREASED_nan'
 'OTHER:SENSITIVITY_IN_VITRO' nan nan 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'PON1' 'CT + TT' 'rs662' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION'
 'PEOPLE' 'DISEASE:ANGINA_PECTORIS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METHADONE' 'CYP2B6' '*6/*6' 'CYP2B6*1, CYP2B6*6' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:(S)-METHADONE_PLASMA_LEVELS' nan nan
 'CAUTION_DOSE_ADJUST']
['TRIMIPRAMINE' 'CYP2D6' '*4/*4 + *3/*5 + *3/*3'
 'CYP2D6*1, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:SEDATION' 'HEALTHY' nan
 'CAUTION_SIDE_EFFECT']
['ASPIRIN' 'IL1B' 'A' 'rs1143627' 'TOXICITY' 'nan_nan'
 'DISEASE:PEPTIC_ULCER_DISEASE' 'PEOPLE' 'DISEASE:CARDIOVASCULAR_DISEASE'
 'CAUTION_DOSE_ADJUST']
['CARBOPLATIN, PACLITAXEL' 'NRG3' 'G' 'rs1649942' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'WOMEN'
 'OTHER:OVARIAN_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'SLCO1B1' 'C' 'rs4149056' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:STEROL/BILE_ACID_METABOLITES' 'PEOPLE' 'DISEASE:HYPERCHOLESTEROLEMIA'
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' '*6/*6' 'CYP2B6*6' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_EFAVIRENZ_LEVELS' 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:NON-RESPONSIVENESS' 'PEOPLE'
 'DISEASE:ANGINA_PECTORIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CAFFEINE' 'ADORA2A' 'TT' 'rs5751876' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:ANXIETY_DISORDERS' nan nan 'CAUTION_SIDE_EFFECT']
['PACLITAXEL, PLATINUM_COMPOUNDS' 'NAT2' 'AG + GG' 'rs1208' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:LUNG_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NEMONAPRIDE' 'ANKK1' 'A' 'rs1800497' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:PROLACTIN_CONCENTRATIONS' 'WOMEN' 'OTHER:SCHIZOPHRENIA'
 'CAUTION_SIDE_EFFECT']
['METHOTREXATE' 'SLC19A1' 'TT' 'rs1051266' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS'
 'PEOPLE' 'DISEASE:RHEUMATOID_ARTHRITIS' 'CAUTION_DOSE_ADJUST']
['FLUVOXAMINE' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['METHOTREXATE' 'GGH' 'AA' 'rs3758149' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS' 'PEOPLE'
 'DISEASE:RHEUMATOID_ARTHRITIS' 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLATE_MOFETIL' 'IMPDH2' 'G' 'rs11706052' 'OTHER' 'INCREASED_nan'
 'OTHER:INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*2/*2 + *1/*2' 'CYP2C19*1, CYP2C19*2'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:_ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR)' 'PEOPLE'
 'DISEASE:ANGINA_PECTORIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MYCOPHENOLATE_MOFETIL' 'SLCO1B3' 'G' 'rs4149117' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:DOSE-NORMALIZED__CMAX_AND_DOSE-NORMALIZED__AUC0TO12_H' 'PEOPLE'
 'OTHER:KIDNEY_TRANSPLANTS' 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*2/*2' 'CYP2C19*1, CYP2C19*2'
 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION'
 'PEOPLE' 'DISEASE:ANGINA_PECTORIS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2 + *3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR)' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METHOTREXATE' 'MTHFR' 'GG' 'rs1801131' 'EFFICACY' 'DECREASED_nan'
 'OTHER:EVENT-FREE_SURVIVAL' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['FLECAINIDE' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['DAUNORUBICIN' 'SZRD1' 'T' 'rs6603859' 'OTHER, METABOLISM/PK'
 'DECREASED_nan' 'PK:IC50' nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2'
 'CYP2C19*1, CYP2C19*2, CYP2C19*17' 'EFFICACY' 'INCREASED_nan'
 'OTHER:PLATELET_REACTIVITY' 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['DAUNORUBICIN' nan 'GG' 'rs7929521' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:IC50' nan nan 'CAUTION_DOSE_ADJUST']
['AZACITIDINE' 'TYMS' 'del/del' 'rs11280056' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:MYELODYSPLASTIC_SYNDROMES'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['DAUNORUBICIN' 'MAN1B1' 'T' 'rs3750518' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:IC50' nan nan 'CAUTION_DOSE_ADJUST']
['OXYCODONE' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:MEAN_OXYMORPHONE/OXYCODONE_RATIOS'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['DESIPRAMINE' 'CYP2D6' '*10/*10 + *5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['GEFITINIB' 'EGFR' '(CA)16/(CA)16' 'rs11568315' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MERCAPTOPURINE, THIOGUANINE' 'TPMT' '*1/*3C'
 'TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OLANZAPINE' 'GSTM3' 'CCT/CCT' 'rs1799735' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:AREA_UNDER_THE_CURVE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:AREA_UNDER_THE_CURVE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['ANASTROZOLE' 'CYP19A1' 'AA' 'rs727479' 'EFFICACY' 'INCREASED_nan'
 'OTHER:RECURRENCE_FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OXYCODONE' 'CYP2D6' '*4/*4 + *4/*6'
 'CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS'
 'PEOPLE' 'DISEASE:NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['FLUVASTATIN' 'SLCO1B1' 'CC' 'rs11045819' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:LDL-C_REDUCTION' 'PEOPLE' 'DISEASE:HYPERCHOLESTEROLEMIA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OXYCODONE' 'CYP2D6' '*4/*4 + *3/*4'
 'CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS'
 'PEOPLE' 'DISEASE:NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' '*18/*18' 'CYP2B6*18' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_EFAVIRENZ_LEVELS' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CYCLOPHOSPHAMIDE, DOXORUBICIN' 'NQO2' 'C' 'rs1143684' 'EFFICACY'
 'nan_nan'
 'EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE'
 'PEOPLE' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['PIOGLITAZONE' 'CYP2C8' '*1/*2 + *2/*2' 'CYP2C8*1, CYP2C8*2'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:M-III:PIOGLITAZONE_AUC0-48_RATIO_AND_M-III:M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['IBUPROFEN' 'CYP2C8' '*1/*2' 'CYP2C8*1, CYP2C8*2' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:R-IBUPROFEN_METABOLISM' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' 'A' 'rs4244285' 'TOXICITY' 'nan_nan'
 "SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH, NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP"
 'PEOPLE' 'OTHER:DRUG-ELUTING_STENTS' 'CAUTION_DOSE_ADJUST']
['NAN' 'IRS1' 'C' 'rs1801123' 'OTHER' 'nan_nan'
 'OTHER:LYMPH_NODE_INVOLVEMENT' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['ESTRADIOL' nan 'A' 'rs1864729' 'OTHER' 'INCREASED_nan'
 'OTHER:PLASMA_LEVEL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['GEFITINIB' 'EGFR' '(CA)16/(CA)16 + (CA)16/(CA)17' 'rs11568315'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:MEDIAN_SURVIVAL_TIME' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['GEFITINIB' 'EGFR' '(CA)16/(CA)16 + (CA)16/(CA)17' 'rs11568315'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:RESPONSE_RATE_(RR)' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'EGFR' '(CA)16/(CA)16 + (CA)16/(CA)17' 'rs11568315' 'NAN'
 'INCREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*2 + *1/*3 + *2/*3'
 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['GEFITINIB' 'EGFR' '(CA)16/(CA)16 + (CA)16/(CA)17' 'rs11568315'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:SURVIVAL_TIME' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION'
 nan nan 'CAUTION_DOSE_ADJUST']
['GEFITINIB' 'EGFR' '(CA)16/(CA)16 + (CA)16/(CA)17' 'rs11568315'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:BETTER_CLINICAL_RESPONSE' nan
 'EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN' 'CHILDREN' nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY' 'nan_nan'
 'EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION'
 nan nan 'CAUTION_DOSE_ADJUST']
['FLUVOXAMINE, PAROXETINE' 'SLC6A4'
 'HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C'
 'SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T'
 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['RISPERIDONE' 'CYP2D6' '*4/*5 + *4/*6 + *3/*4 + *4/*4'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6' 'OTHER'
 'DECREASED_nan' 'OTHER:WAKEFULNESS_ACTIVITY_LEVEL' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['NAN' 'IGFBP3' 'T' 'rs2854744' 'OTHER' 'nan_nan' 'OTHER:TUMOR_SIZE'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*4/*5' 'CYP2D6*1, CYP2D6*4, CYP2D6*5'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:PAROXETINE_PLASMA_CONCENTRATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['FLUOXETINE' 'CYP2D6' '*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO'
 'CHILDREN' 'DISEASE:DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR' 'ITPA' 'CC' 'rs1127354'
 'OTHER' 'nan_nan'
 'SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN'
 'PEOPLE' 'DISEASE:HEPATITIS' 'CAUTION_DOSE_ADJUST']
['NAN' 'IFNL3' 'TT' 'rs8099917' 'NAN' 'INCREASED_nan'
 'OTHER:BASELINE_VIRAL_LOAD' 'PEOPLE' 'DISEASE:HEPATITIS'
 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*1/*4 + *1/*5' 'CYP2D6*1, CYP2D6*4, CYP2D6*5'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY'
 'WOMEN' nan 'CAUTION_DOSE_ADJUST']
['DICLOFENAC' 'CYP2C8' '*1/*3 + *3/*3' 'CYP2C8*1, CYP2C8*3'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*3/*4' 'CYP2D6*1, CYP2D6*3, CYP2D6*4'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:PAROXETINE_PLASMA_CONCENTRATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR' 'IFNL4' 'TT/TT'
 'rs11322783' 'TOXICITY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION' 'CAUTION_SIDE_EFFECT']
['IBUPROFEN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:RACEMIC, S-IBUPROFEN_AND_R-IBUPROFEN_METABOLISM, WITH_INCREASE_OF_AUC(0-INFINITY)_AND_REDUCTION_OF_CLEARANCE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TENOXICAM' 'CYP2C9' '*1/*2' 'CYP2C9*1, CYP2C9*2' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TENOXICAM' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE' 'CYP2B6' '*6'
 'CYP2B6*1, CYP2B6*6' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_4BETA-OHC/CHOL_RATIO' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['PIROXICAM' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NICOTINE' 'CYP2A6' '*4 + *10 + *9'
 'CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10' 'METABOLISM/PK' 'DECREASED_nan'
 "PK:PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT)"
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*17' 'CYP2C19*1, CYP2C19*17' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PAROXETINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PAROXETINE_LEVELS' 'PEOPLE'
 'DISEASE:OBSESSIVE_COMPULSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['IBUPROFEN' 'CYP2C9' '*1/*2' 'CYP2C9*1, CYP2C9*2' 'OTHER' 'DECREASED_nan'
 'OTHER:INOS_EXPRESSION' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['IBUPROFEN' 'CYP2C8' '*1/*3' 'CYP2C8*1, CYP2C8*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:R-IBUPROFEN_METABOLISM' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['FLUOROURACIL' 'TYMS'
 '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2'
 'rs45445694' 'EFFICACY' 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL'
 'PEOPLE' 'OTHER:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PIROXICAM' 'CYP2C9' '*1/*2' 'CYP2C9*1, CYP2C9*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PIROXICAM' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'INCREASED_nan'
 "PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE"
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PIROXICAM' 'CYP2C9' '*1/*2' 'CYP2C9*1, CYP2C9*2' 'METABOLISM/PK'
 'INCREASED_nan'
 "PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE"
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CITALOPRAM, ESCITALOPRAM' 'CYP2D6' 'A' 'rs1065852' 'OTHER' 'nan_nan'
 'OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['HYDROCHLOROTHIAZIDE' 'ACE' 'del/del' 'rs1799752' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:REDUCTION_IN_BLOOD_PRESSURE' 'MEN'
 'DISEASE:ESSENTIAL_HYPERTENSION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:PLATELET_AGGREGATION' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:MYOCARDIAL_INFARCTION'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN' 'HLA-B' '*15:02' 'HLA-B*15:02'
 'TOXICITY' 'nan_RISK'
 'SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME'
 nan nan 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*1/*1xN' 'CYP2D6*1, CYP2D6*1XN' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:CLEARANCE_OF_S(+)_MIRTAZAPINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_IN_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MIRTAZAPINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METOPROLOL' 'ADRB2' 'CG' 'rs1042714' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:TRIGLYCERIDES' 'PEOPLE' 'DISEASE:HYPERTENSION'
 'CAUTION_SIDE_EFFECT']
['WARFARIN' 'CYP2C9' '*1/*2 + *1/*3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:TIME_TO_THERAPEUTIC_INR' 'CHILDREN'
 'DISEASE:NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:INTOLERANCE' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_SIDE_EFFECT']
['TACROLIMUS' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CAFFEINE' 'ADORA2A' 'TTTTTTT/TTTTTTT' 'rs35060421' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:ANXIETY' 'HEALTHY' nan 'CAUTION_SIDE_EFFECT']
['ZONISAMIDE' 'HLA-A' '*02:07' 'HLA-A*02:07' 'TOXICITY' 'nan_nan'
 'DISEASE:STEVENS-JOHNSON_SYNDROME' nan nan 'CAUTION_DOSE_ADJUST']
['PHENOBARBITAL' 'HLA-B' '*51:01' 'HLA-B*51:01' 'TOXICITY' 'nan_nan'
 'DISEASE:STEVENS-JOHNSON_SYNDROME' nan nan 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*17/*17' 'CYP2C19*1, CYP2C19*17'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:TROUGH_CONCENTRATIONS' 'CHILDREN'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['LAMIVUDINE, NEVIRAPINE, STAVUDINE' 'HLA-B' '*35:05' 'HLA-B*35:05'
 'TOXICITY' 'nan_nan' 'SIDE_EFFECT:EXANTHEMA' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS'
 'CHILDREN' 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW'
 'CHILDREN' 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['FOLFIRI' 'UGT1A1' '*1/*28 + *28/*28' 'UGT1A1*1, UGT1A1*28' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:DEATH' 'PEOPLE' 'OTHER:COLORECTAL_NEOPLASMS'
 'CAUTION_SIDE_EFFECT']
['METHOTREXATE' 'ABCC2' 'AG + GG' 'rs3740065' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_LEVEL' 'CHILDREN'
 'OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS'
 'CHILDREN' 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['METOPROLOL' 'ADRB2' 'CC' 'rs1042714' 'TOXICITY' 'DECREASED_nan'
 'SIDE_EFFECT:TOTAL_CHOLESTEROL' 'PEOPLE' 'DISEASE:HYPERTENSION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METHOTREXATE' 'ABCC4' 'GG + GT' 'rs9516519' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:PLASMA_LEVEL' 'CHILDREN'
 'OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS'
 'CHILDREN' 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS'
 'CHILDREN' 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A5' '*1/*1 + *1/*3' 'CYP3A5*1, CYP3A5*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:TROUGH_CONCENTRATIONS' 'CHILDREN'
 'DISEASE:LIVER_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*2/*2 + *2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:S-CIT_SERUM_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*2/*2 + *2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEAN_ESCITALOPRAM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'SLC6A4' 'HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RESPONSE_WHEN_MEASURED_BY_THE_GERIATRIC_DEPRESSION_SCALE_AT_DAY_7_AND_DAY_28'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ESCITALOPRAM' 'CYP2C19' '*17/*17' 'CYP2C19*1, CYP2C19*17'
 'DOSAGE, METABOLISM/PK' 'DECREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3'
 'DOSAGE, METABOLISM/PK' 'INCREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'SLC6A4' 'HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'nan_nan'
 'EFFICACY:POSITIVE_CORRELATION_OF_PAROXETINE_CONCENTRATION_WITH_IMPROVEMENT_IN_HAMD_SCORES_AT_WEEK_2'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2D6' '*4/*41' 'CYP2D6*1, CYP2D6*4, CYP2D6*41'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*3 + *2/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'TOXICITY' 'INCREASED_nan'
 'EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS'
 nan nan 'CAUTION_SIDE_EFFECT']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2' 'TOXICITY'
 'INCREASED_nan'
 'EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS'
 nan nan 'CAUTION_SIDE_EFFECT']
['ESCITALOPRAM' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'DOSAGE, METABOLISM/PK' 'INCREASED_nan' 'PK:SERUM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:MYOCARDIAL_INFARCTION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CITALOPRAM' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2/*2' 'CYP2C19*2' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' 'DISEASE:ANGINA_PECTORIS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL' 'UGT1A1' '*28'
 'UGT1A1*28' 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL'
 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL' 'UGT1A1' '*60'
 'UGT1A1*60' 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL'
 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*10/*10' 'CYP2D6*1, CYP2D6*10' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'UGT2B15' '*2/*2 + *1/*2'
 'UGT2B15*1, UGT2B15*2' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['IRINOTECAN' 'UGT1A1' '*1/*28 + *28/*28' 'UGT1A1*1, UGT1A1*28' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:ASTHENIA' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_SIDE_EFFECT']
['DOCETAXEL' 'SLCO1B3' 'A' 'rs3834935' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:AUC' 'PEOPLE' 'DISEASE:NASOPHARYNGEAL_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID' 'GABRA1' 'GG' 'rs2279020'
 'EFFICACY' 'nan_nan' 'EFFICACY:DRUG-RESISTANT_PHENOTYPE' 'PEOPLE'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CITALOPRAM, ESCITALOPRAM' nan 'A' 'rs1074145' 'OTHER' 'nan_nan'
 'OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2C19' '*2/*2'
 'CYP2C19*1, CYP2C19*2' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*1/*17' 'CYP2C19*1, CYP2C19*17' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_AGGREGATION_INHIBITION' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID' 'GABRA1' 'G' 'rs2279020'
 'EFFICACY' 'nan_nan' 'EFFICACY:DRUG-RESISTANT_PHENOTYPE' 'PEOPLE'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['METOPROLOL' 'CYP2D6'
 '*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41'
 'OTHER' 'nan_nan' 'OTHER:GREATER_HEART_RATE_(HR)_REDUCTION' nan nan
 'CAUTION_DOSE_ADJUST']
['CYCLOPHOSPHAMIDE' 'CYP2B6' 'CT' 'rs3211371' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RECURRENCE' 'PEOPLE' 'DISEASE:LYMPHOMA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2 + *2/*17'
 'CYP2C19*1, CYP2C19*2, CYP2C19*17' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_AGGREGATION' nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' 'A' 'rs4244285' 'EFFICACY' 'nan_nan'
 'OTHER:HIGH_PLATELET_REACTIVITY_(HPR)' nan nan 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'SLC6A4' 'L allele-rs25531T/L allele-rs25531T'
 'SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T'
 'OTHER' 'nan_nan'
 'OTHER:A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EFFICACY' nan
 'OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EFFICACY' nan
 'OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['AMITRIPTYLINE' 'CYP2D6' '*41' 'CYP2D6*1, CYP2D6*41'
 'OTHER, METABOLISM/PK' 'INCREASED_nan' 'PK:PLASMA_NORTRIPTYLINE' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['CYCLOPHOSPHAMIDE' 'CYP2B6' 'CT' 'rs3211371' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:LYMPHOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ATORVASTATIN' 'LEPR' 'GG' 'rs1805094' 'OTHER' 'INCREASED_nan'
 'OTHER:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'CAUTION_DOSE_ADJUST']
['BUSULFAN, CYTARABINE, ETOPOSIDE' 'ABCC3' 'G' 'rs4148405'
 'EFFICACY, TOXICITY' 'DECREASED_nan' 'OTHER:DISEASE-FREE_SURVIVAL'
 'PEOPLE' 'DISEASE:ACUTE_MYELOID_LEUKEMIA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTIPSYCHOTICS' 'COMT' 'A' 'rs4680' 'OTHER' 'INCREASED_nan'
 'OTHER:METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['MERCAPTOPURINE, THIOGUANINE' 'TPMT' '*1/*3C' 'TPMT*1, TPMT*3C'
 'TOXICITY' 'nan_nan' 'SIDE_EFFECT:THROMBOCYTOPENIA' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['FLUTICASONE_PROPIONATE' 'CD14, TMCO6' 'AA + AG' 'rs2569190' 'OTHER'
 'DECREASED_nan' 'EFFICACY:FEV1/FVC_RATIO' 'CHILDREN' 'DISEASE:ASTHMA'
 'CAUTION_DOSE_ADJUST']
['ISONIAZID, RIFAMPIN' 'GSTT1' nan 'GSTT1 NULL' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:SERUM_HYDRAZINE_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:TUBERCULOSIS' 'CAUTION_DOSE_ADJUST']
['ISONIAZID, RIFAMPIN' 'GSTM1' nan 'GSTM1 NULL' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:SERUM_HYDRAZINE_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:TUBERCULOSIS' 'CAUTION_DOSE_ADJUST']
['FLUOXETINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'nan_nan'
 'PK:SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['NAN' 'NAT2' nan 'NAT2 DEFICIENCY' 'OTHER' 'nan_nan'
 'DISEASE:INSULIN_RESISTANCE' nan nan 'CAUTION_DOSE_ADJUST']
['FLUOXETINE' 'CYP2C9' '*1/*2 + *1/*3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['NORTRIPTYLINE' 'CYP2D6' '*1/*4 + *1/*5' 'CYP2D6*1, CYP2D6*4, CYP2D6*5'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['SPIRONOLACTONE' 'ACE'
 'ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del'
 'rs1799752' 'EFFICACY' 'nan_nan'
 'EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION, END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME'
 'PEOPLE' 'OTHER:CHRONIC_HEART_FAILURE' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT'
 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:HEPATITIS_C_VIRUS_INFECTION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'APOE' 'TT' 'rs429358' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'APOE' 'CC' 'rs7412' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ATORVASTATIN, QUINAPRIL' 'ACE' 'del/del' 'rs1799752' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:REDUCTION_IN_D-DIMER_LEVELS' 'MEN'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TIMOLOL' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER'
 'EFFICACY, METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION' 'MEN'
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['LANSOPRAZOLE' 'CYP2C19' nan 'CYP2C19 NORMAL_METABOLIZER' 'METABOLISM/PK'
 'DECREASED_nan' 'OTHER:GASTRIC_PH' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['RABEPRAZOLE' 'CYP2C19' nan 'CYP2C19 NORMAL_METABOLIZER' 'EFFICACY'
 'DECREASED_nan' 'OTHER:GASTRIC_PH' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'AREG' 'A' 'rs1615111' 'OTHER' 'DECREASED_nan'
 'OTHER:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:ADENOCARCINOMA'
 'CAUTION_DOSE_ADJUST']
['CISPLATIN, EPIRUBICIN, FLUOROURACIL' 'C18orf56, TYMS'
 '(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2'
 'rs45445694' 'EFFICACY' 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL'
 'PEOPLE' 'DISEASE:NEOPLASM_OF_ESOPHAGUS, DISEASE:STOMACH_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ATORVASTATIN, QUINAPRIL' 'ACE' 'del/del' 'rs1799752' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:REDUCTION_IN_IL-6_LEVELS' 'MEN'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ATORVASTATIN, QUINAPRIL' 'ACE' 'del/del' 'rs1799752' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:REDUCTION_IN_CRP_LEVELS' 'MEN'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C9' '*2/*2' 'CYP2C9*1, CYP2C9*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_AGGREGATION' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['VINCRISTINE' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:AVERAGE_CUMULATIVE_NEUROTOXICITY_GRADE'
 'CHILDREN' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ASPIRIN, CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2, CYP2C19*17'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:PLATELET_AGGREGATION' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TOLTERODINE' 'CYP2D6' '*10/*10 + *5/*10' 'CYP2D6*1, CYP2D6*5, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['VALPROIC_ACID' 'UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9' 'G' 'rs6759892'
 'DOSAGE, METABOLISM/PK' 'INCREASED_nan' 'PK:GLUCURONIDATION' nan nan
 'CAUTION_DOSE_ADJUST']
['VALPROIC_ACID' 'UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9' 'G' 'rs2070959'
 'DOSAGE, METABOLISM/PK' 'INCREASED_nan' 'PK:GLUCURONIDATION' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'MED12L, P2RY12' 'T/del' 'rs5853517' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PLATELET_AGGREGATION' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['EXEMESTANE' nan 'TT' 'rs16964189' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID' 'ABCB1' 'T' 'rs2032582'
 'EFFICACY' 'nan_nan' 'EFFICACY:DRUG-RESISTANT_PHENOTYPE' 'PEOPLE'
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['FLUOROURACIL, LEUCOVORIN, OXALIPLATIN' 'TYMS'
 '(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3'
 'rs45445694' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP4F2' '*3' 'CYP4F2*1, CYP4F2*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:TIME_TO_THERAPEUTIC_INR' 'PEOPLE' 'DISEASE:ATRIAL_FIBRILLATION'
 'CAUTION_DOSE_ADJUST']
['METOPROLOL' 'CYP2D6' '*1/*4 + *4/*4' 'CYP2D6*1, CYP2D6*4'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:PLASMA_METOPROLOL_CONCENTRATIONS' nan
 nan 'CAUTION_DOSE_ADJUST']
['"ACE_INHIBITORS, PLAIN", "BETA_BLOCKING_AGENTS", "CALCIUM_CHANNEL_BLOCKERS", "DIGOXIN", "DIURETICS"'
 'ACE' 'del' 'rs1799752' 'EFFICACY' 'INCREASED_nan' 'EFFICACY:MORTALITY'
 'PEOPLE' 'DISEASE:HEART_FAILURE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['IVACAFTOR, TEZACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'OTHER'
 'DECREASED_nan' 'SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION'
 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS' 'CAUTION_DOSE_ADJUST']
['DESIPRAMINE' 'CYP2D6' '*1/*1' 'CYP2D6*1, CYP2D6*4, CYP2D6*5'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:METABOLIC_RATIOS_OF_DESIPAMINE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PAMAQUINE' 'G6PD' nan 'G6PD DEFICIENCY' 'TOXICITY' 'nan_nan'
 'DISEASE:HEMOLYSIS' nan 'OTHER:G6PD_DEFICIENT_MICE' 'CAUTION_DOSE_ADJUST']
['METOPROLOL' 'CYP2D6' '*1/*4 + *4/*4' 'CYP2D6*1, CYP2D6*4'
 'EFFICACY, OTHER' 'INCREASED_nan'
 'OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION'
 nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PRIMAQUINE' 'G6PD' nan 'G6PD DEFICIENCY' 'TOXICITY' 'nan_nan'
 'DISEASE:HEMOLYSIS' nan 'OTHER:G6PD_DEFICIENT_MICE' 'CAUTION_DOSE_ADJUST']
['HMG_COA_REDUCTASE_INHIBITORS' nan 'A' 'rs3764261' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROTECTION_AGAINST_MYOCARDIAL_INFARCTION' nan
 nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PHENPROCOUMON' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'EFFICACY' 'DECREASED_nan' 'SIDE_EFFECT:TIME_BELOW_THERAPEUTIC_RANGE' nan
 nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OSIMERTINIB' 'CYP2A6' 'CC' 'rs28399433' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'OTHER:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ETHANOL' 'GHSR' 'AG' 'rs2948694' 'OTHER' 'nan_nan' 'OTHER:WEIGHT' nan
 nan 'CAUTION_DOSE_ADJUST']
['NICOTINE' 'CYP2A6' '*46/*46' 'CYP2A6*1, CYP2A6*46' 'NAN' 'INCREASED_nan'
 'OTHER:CIGARETTES_PER_DAY' nan nan 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:STEADY_STATE_CONCENTRATION_PER_DOSAGE' nan
 'DISEASE:EPILEPSY' 'CAUTION_DOSE_ADJUST']
['CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID' 'SCN2A' 'A' 'rs17183814'
 'EFFICACY' 'nan_nan' 'EFFICACY:NON-RESPONSE' 'PEOPLE' 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'EFFICACY' 'nan_nan'
 'EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4' nan nan
 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'ERCC2' 'T' 'rs1799793' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:NEOPLASM_OF_ESOPHAGUS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*1, CYP2C9*2' 'DOSAGE' 'nan_nan'
 'EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT' nan nan 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*1/*4' 'CYP2D6*1, CYP2D6*4, CYP2D6*41'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PAROXETINE_SERUM_CONCENTRATIONS_(CMIN)' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['IBUPROFEN' 'CYP2C9' '*3' 'CYP2C9*3' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:DURATION_OF_INHIBITION_OF_PROSTANOIDS' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PLASMA_CONCENTRATION' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:THE_MAXIMAL_ELIMINATION_RATE_(VMAX)' nan 'DISEASE:EPILEPSY'
 'CAUTION_DOSE_ADJUST']
['ACETAMINOPHEN' 'CYP2E1' '*1/*5B' 'CYP2E1*1, CYP2E1*5B' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:ELIMINATION_RATE' 'PEOPLE'
 'DISEASE:ALCOHOLIC_LIVER_DISEASES' 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE' 'TPMT' '*1/*3A' 'TPMT*1, TPMT*3A' 'TOXICITY'
 'INCREASED_nan' 'PK:PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS'
 'CHILDREN' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3 + *3/*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE'
 'DECREASED_nan' 'OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS' nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE, EFFICACY' 'nan_nan'
 'EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION' nan
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*1/*3 + *1/*4' 'CYP2C9*1, CYP2C9*3, CYP2C9*4'
 'DOSAGE' 'DECREASED_nan' 'OTHER:WARFARIN_DOSE' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE'
 nan nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BUPROPION' 'CYP2B6' '*18' 'CYP2B6*18' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:HYDROXYBUPROPION_CONCENTRATIONS' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PLASMA_CONCENTRATION' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*1' 'CYP2C9*1' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PLASMA_CONCENTRATION' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2C19' '*2/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['PACLITAXEL' 'CYP2C8' '*3' 'CYP2C8*3' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:CLERANCE_OF_PACLITAXEL' 'WOMEN' 'DISEASE:OVARIAN_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['BUPROPION' 'CYP2B6' '*6' 'CYP2B6*1, CYP2B6*6' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*2' 'EFFICACY' 'nan_nan'
 'EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*3' 'CYP2C19*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION'
 nan nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP3A4' 'C/C' 'rs2242480' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['DAUNORUBICIN' 'NRP2' 'C' 'rs10932125' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:IC50' nan nan 'CAUTION_DOSE_ADJUST']
['METOPROLOL' 'CYP2D6' 'del/del' 'rs5030655' 'OTHER' 'INCREASED_nan'
 'PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL' nan nan 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'SLC6A4' '(CCCACCCGA)12/(CCCACCCGA)12' 'rs57098334'
 'NAN' 'nan_nan' 'EFFICACY:LACK_OF_REMISSION_AND_LACK_OF_RESPONSE'
 'PEOPLE' 'DISEASE:DEPRESSION' 'CAUTION_DOSE_ADJUST']
['VALPROIC_ACID' 'UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9' 'C' 'rs1105879'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:GLUCURONIDATION' nan nan
 'CAUTION_DOSE_ADJUST']
['ATENOLOL' 'ADRB1' 'CC' 'rs1801253' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_BLOOD_PRESSURE' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['AMITRIPTYLINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:AMITRIPTYLINE/(E)-10-_OH-AT_RATIO' nan nan
 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:NORTRIPTYLINE/(E)-10-OH-NT_RATIO' nan nan
 'CAUTION_DOSE_ADJUST']
['REPAGLINIDE' 'SLCO1B1' '*37/*37' 'SLCO1B1*1, SLCO1B1*37' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' '*1' 'CYP2B6*1' 'EFFICACY, METABOLISM/PK'
 'DECREASED_nan' 'PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TEGAFUR' 'CYP2A6' '*1' 'CYP2A6*1' 'OTHER, METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_FLUOROURACIL' 'PEOPLE' 'DISEASE:NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['PHENYTOIN' 'CYP2C9' '*1/*2 + *1/*3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'TOXICITY' 'INCREASED_nan' 'SIDE_EFFECT:ADVERSE_DRUG_REACTIONS' nan
 'DISEASE:EPILEPSY' 'CAUTION_SIDE_EFFECT']
['ATORVASTATIN' 'UGT1A3' '*2/*2' 'UGT1A3*1, UGT1A3*2'
 'EFFICACY, METABOLISM/PK' 'INCREASED_nan' 'PK:ATORVASTATIN_LACTONIZATION'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ATORVASTATIN' 'UGT1A3' '*2' 'UGT1A3*1, UGT1A3*2'
 'EFFICACY, METABOLISM/PK' 'DECREASED_nan'
 'EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['DOXEPIN' 'CYP2C9' '*3/*3' 'CYP2C9*3' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP2C19' '*2/*2' 'CYP2C19*2' 'OTHER' 'INCREASED_nan'
 'OTHER:HOSPITAL_STAY' 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['ROSIGLITAZONE' 'CYP2C8' '*3' 'CYP2C8*3' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:MEAN_ABSOLUTE_DIFFERENCE_IN_HBA1C' 'PEOPLE'
 'DISEASE:DIABETES_MELLITUS_T2' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NORTRIPTYLINE' 'CYP2D6' '*1/*2xN' 'CYP2D6*1, CYP2D6*2XN' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['PRAVASTATIN' 'SLCO1B1' '*15' 'SLCO1B1*1, SLCO1B1*15' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['AMITRIPTYLINE' 'CYP2C19' '*2/*2' 'CYP2C19*1, CYP2C19*2' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)'
 nan nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)'
 nan nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'CYP2C19' '*17' 'CYP2C19*1, CYP2C19*17' 'OTHER' 'nan_RISK'
 'DISEASE:PEPTIC_ULCER_DISEASE' nan nan 'CAUTION_DOSE_ADJUST']
['CAFFEINE' 'ADORA2A' 'TT' 'rs5751876' 'OTHER' 'INCREASED_nan'
 'SIDE_EFFECT:ANXIETY' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' '*6/*6' 'CYP2B6*6' 'TOXICITY, METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATION' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_SIDE_EFFECT']
['ATORVASTATIN' 'CYP3A5' '*3/*3' 'CYP3A5*1, CYP3A5*3' 'TOXICITY'
 'INCREASED_nan'
 'SIDE_EFFECT:SERUM_CREATINE_KINASE_LEVELS_(INCREASED_RISK_OF_MYALGIA_AND_GREATER_DEGREE_OF_MUSCLE_DAMAGE)'
 nan nan 'CAUTION_SIDE_EFFECT']
['METFORMIN' 'SLC22A1' 'GTAAGTTG' 'rs36056065' 'TOXICITY, METABOLISM/PK'
 'nan_nan' 'SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS' 'PEOPLE'
 'DISEASE:DIABETES_MELLITUS_T2' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*17' 'CYP2C19*17' 'EFFICACY' 'nan_nan'
 'EFFICACY:ENHANCED_RESPONSE_TO_CLOPIDOGREL_(AS_MEASURED_BY_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION)'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['EFAVIRENZ, OMEPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4' nan nan
 'CAUTION_DOSE_ADJUST']
['MERCAPTOPURINE' 'TPMT' '*1/*3A' 'TPMT*1, TPMT*3A' 'TOXICITY'
 'INCREASED_nan' 'PK:PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES'
 'CHILDREN' 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['PRAVASTATIN' 'SLCO1B1' '*1/*15' 'SLCO1B1*1, SLCO1B1*15, SLCO1B1*37'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['PRAVASTATIN' 'SLCO1B1' '*1/*15' 'SLCO1B1*1, SLCO1B1*15' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*13' 'CYP2C9*1, CYP2C9*13' 'DOSAGE'
 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION' nan
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PRAVASTATIN' 'SLCO1B1' '*15/*15' 'SLCO1B1*1, SLCO1B1*15' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173' nan nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['DOXEPIN' 'CYP2D6' '*3/*5' 'CYP2D6*3, CYP2D6*5' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['DOXEPIN' 'CYP2D6' '*4/*5' 'CYP2D6*4, CYP2D6*5' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*13' 'CYP2C9*1, CYP2C9*13' 'EFFICACY' 'nan_nan'
 'EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE, EFFICACY' 'nan_nan'
 'EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*14' 'CYP2C9*1, CYP2C9*14' 'DOSAGE'
 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:MEAN_INR_VALUES_IN_PATIENTS_WITH_HEART_VALVE_REPLACEMENT' nan
 nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2B6' '*5' 'CYP2B6*5' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS'
 nan 'OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION'
 'CAUTION_DOSE_ADJUST']
['VENLAFAXINE' 'CYP2D6' '*10/*10' 'CYP2D6*10' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:CMAX_AND_AUC_OF_VENLAFAXINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*2/*3' 'CYP2C9*2, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:MEAN_INR_VALUE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*2' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*3' 'CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_DOSE' nan nan 'CAUTION_DOSE_ADJUST']
['VENLAFAXINE' 'CYP2D6' '*1/*10' 'CYP2D6*1, CYP2D6*10' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:CMAX_AND_AUC_OF_VENLAFAXINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*14' 'CYP2C9*1, CYP2C9*14' 'EFFICACY' 'nan_nan'
 'EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5'
 nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5'
 nan nan 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP2D6' '*4/*10' 'CYP2D6*1, CYP2D6*4, CYP2D6*10'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:FREQUENCY_OF_REMITTERS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['LANSOPRAZOLE' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'DECREASED_nan' 'OTHER:INTRAGASTRIC_PH' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['LANSOPRAZOLE' 'CYP2C19' '*1/*2 + *1/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'DECREASED_nan'
 'OTHER:INTRAGASTRIC_PH' 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)'
 nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TRAMADOL' 'CYP2D6' '*10/*10' 'CYP2D6*1, CYP2D6*10' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['TRAMADOL' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4'
 'EFFICACY, METABOLISM/PK' 'DECREASED_nan'
 'EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OMEPRAZOLE' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS'
 'PEOPLE' 'DISEASE:ULCER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PAROXETINE' 'CYP2D6' '*4/*4 + *3/*4' 'CYP2D6*3, CYP2D6*4'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY'
 'WOMEN' nan 'CAUTION_DOSE_ADJUST']
['TRAMADOL' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'DOSAGE, EFFICACY'
 'DECREASED_nan' 'EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL'
 nan nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*3 + *3/*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE'
 nan nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TAMOXIFEN' 'CYP2D6' '*6/*7' 'CYP2D6*6, CYP2D6*7' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ESCITALOPRAM' 'CYP2D6' '*5/*10' 'CYP2D6*1, CYP2D6*5, CYP2D6*10'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:FREQUENCY_OF_REMITTERS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' '*3/*6' 'CYP2D6*3, CYP2D6*6' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['TRAMADOL' 'CYP2D6' '*3/*4' 'CYP2D6*1, CYP2D6*3, CYP2D6*4'
 'DOSAGE, EFFICACY' 'DECREASED_nan'
 'EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOMIPRAMINE' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NORTRIPTYLINE' 'CYP2D6' '*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['OXYCODONE' 'CYP2D6' '*4/*4 + *3/*4' 'CYP2D6*1, CYP2D6*3, CYP2D6*4'
 'METABOLISM/PK' 'nan_nan'
 'PK:MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO'
 nan nan 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*1/*1 + *1/*41' 'CYP2D6*1, CYP2D6*41'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY'
 'WOMEN' nan 'CAUTION_DOSE_ADJUST']
['NORTRIPTYLINE' 'CYP2D6' '*5/*10' 'CYP2D6*1, CYP2D6*5, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['DESIPRAMINE' 'CYP2D6' '*1/*1' 'CYP2D6*1, CYP2D6*3, CYP2D6*4'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:METABOLIC_RATIOS_OF_DESIPAMINE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TRAMADOL' 'CYP2D6' '*2/*10' 'CYP2D6*1, CYP2D6*2, CYP2D6*10'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['TRAMADOL' 'CYP2D6' '*3/*5' 'CYP2D6*1, CYP2D6*3, CYP2D6*5'
 'DOSAGE, EFFICACY' 'DECREASED_nan'
 'EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL' nan nan
 'CAUTION_DOSE_ADJUST']
['NORTRIPTYLINE' 'CYP2D6' '*5' 'CYP2D6*1, CYP2D6*2, CYP2D6*5'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*1/*10 + *1/*5' 'CYP2D6*1, CYP2D6*5, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['COTININE' 'CYP2A6' '*1/*1'
 'CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20' 'METABOLISM/PK'
 'nan_nan' 'PK:SHORTER_CONTININ_HALF-LIFE' 'CHILDREN' nan
 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:CLEARANCE_OF_S(+)_MIRTAZAPINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*1/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PAROXETINE_LEVELS' 'PEOPLE'
 'DISEASE:OBSESSIVE_COMPULSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CLOMIPRAMINE' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CITALOPRAM' 'CYP2C19' '*2/*2 + *2/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'DECREASED_nan' 'PK:ORAL_CLEARANCE_OF_CITALOPRAM'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' '*10/*10 + *1/*10' 'CYP2D6*1, CYP2D6*10'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:_PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*1/*1xN' 'CYP2D6*1, CYP2D6*1XN' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['CODEINE' 'CYP2D6' '*36' 'CYP2D6*1, CYP2D6*36' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['CODEINE' 'CYP2D6' '*1/*1 + *1/*4'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_LEVEL_OF_MORPHINE' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION' 'PEOPLE'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLURBIPROFEN' 'CYP2C9' '*1/*3' 'CYP2C9*1, CYP2C9*3' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:AUC, HIGHER_HALF-LIFE_AND_LOWER_FLURBIPROFEN_CLEARANCE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['DICLOFENAC' 'CYP2C8' '*1/*4 + *4/*4' 'CYP2C8*1, CYP2C8*4'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' nan 'CYP2C19 POOR_METABOLIZER' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT)'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['TIMOLOL' 'CYP2D6' '*3/*3 + *3/*4 + *4/*4 + *5/*4'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE, LONGER_ELIMINATION_HALF-LIVES_)'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['TENOXICAM' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:AUC_AND_HALF-LIFE_TIME_(T1/2)' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['IBUPROFEN' 'CYP2C8' '*1/*3' 'CYP2C8*1, CYP2C8*3' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:INOS_EXPRESSION_AND_FEWER_ADVERSE_EVENTS'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['SULFONAMIDES, UREA_DERIVATIVES' 'TCF7L2' 'CC' 'rs7903146' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS)'
 'PEOPLE' 'DISEASE:DIABETES_MELLITUS_T2' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['LUMACAFTOR' 'CFTR' 'del/del' 'rs113993960' 'TOXICITY' 'INCREASED_nan'
 'EFFICACY:CHANGE_IN_SWEAT_CHLORIDE' 'PEOPLE' 'DISEASE:CYSTIC_FIBROSIS'
 'CAUTION_SIDE_EFFECT']
['ACENOCOUMAROL' 'CYP2C9' '*2/*2 + *2/*3 + *3/*3'
 'CYP2C9*1, CYP2C9*2, CYP2C9*3' 'DOSAGE' 'DECREASED_nan'
 'EFFICACY:ACENOCOUMAROL_DOSE' 'PEOPLE' 'DISEASE:ATRIAL_FIBRILLATION'
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)'
 nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CODEINE' 'CYP2D6' '*1/*10 + *10/*10' 'CYP2D6*1, CYP2D6*10'
 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PLASMA_LEVELS_OF_MORPHINE, M3G_AND_M6G_LEVELS_BUT_NOT_THOSE_OF_CODEINE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['CODEINE' 'CYP2D6' '*1/*1 + *1/*4'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5' 'OTHER' 'INCREASED_nan'
 'OTHER:OROCECCAL_TRANSIT_TIME' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['NAN' 'CYP1B1' 'CC + CG' 'rs1056836' 'NAN' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NEOPLASM_OF_ESOPHAGUS' 'CAUTION_DOSE_ADJUST']
['TETRABENAZINE' 'CYP2D6' nan 'CYP2D6 INTERMEDIATE_METABOLIZER' 'EFFICACY'
 'nan_nan' 'EFFICACY:LESS_ROBUST_TREATMENT_RESPONSE' nan nan
 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*1/*17' 'CYP2C19*1, CYP2C19*17' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:METABOLIC_RATIO_CIT/DCIT_VALUES' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOMIPRAMINE' 'SLC6A4'
 'HTTLPR long form (L allele)/HTTLPR long form (L allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:CLOMIPRAMINE-INDUCED_PROLACTIN_RELEASE' 'HEALTHY' nan
 'CAUTION_SIDE_EFFECT']
['CITALOPRAM' 'CYP2C19' '*1/*2 + *2/*2' 'CYP2C19*1, CYP2C19*2'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:AUC_OF_CITALOPRAM' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'SLC6A4' 'HTTLPR short form (S allele)'
 'SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE)'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PRESENTATION_IN_THE_NON-REPONDER_GROUP' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*2/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PRU' 'PEOPLE' 'DISEASE:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['AZATHIOPRINE, CYCLOSPORINE, PREDNISONE' 'TPMT' '*3A/*3C'
 'TPMT*3A, TPMT*3C' 'TOXICITY' 'nan_SEVERITY' 'SIDE_EFFECT:LEUKOPENIA'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CILOSTAZOL, CLOPIDOGREL' 'CYP2C19' '*2 + *3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ACENOCOUMAROL' 'CYP2C9' '*3' 'CYP2C9*1, CYP2C9*3' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ABACAVIR' 'HLA-B' '*57:01' 'HLA-B*57:01' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:DRUG_HYPERSENSITIVITY' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['IFOSFAMIDE' 'ALDH1A1' 'AA' 'rs3764435' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT' 'rs11322783'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['HMG_COA_REDUCTASE_INHIBITORS' 'ADAMTS1' 'CC' 'rs402007' 'EFFICACY'
 'nan_nan'
 'EFFICACY:THE_MOST_BENEFIT_FROM_STATIN_TREATMENT_IN_REDUCING_THE_RISK_OF_MYOCARDIAL_INFARCTION'
 nan nan 'CAUTION_DOSE_ADJUST']
['LAMOTRIGINE' 'SCN1A' 'C' 'rs3812718' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:TONIC_BLOCK_OF_NA(V)_1.1_CHANNELS' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A5' '*1/*3' 'CYP3A5*1, CYP3A5*3' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:FORMATION_OF_METABOLITES' nan
 'OTHER:HUMAN_KIDNEY_MICROSOMES' 'CAUTION_DOSE_ADJUST']
['PEMETREXED' 'TYMS' 'TTAAAGTTA/TTAAAGTTA' 'rs11280056' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:MESOTHELIOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'SLCO1B1' 'C' 'rs4149056' 'OTHER' 'DECREASED_nan'
 'OTHER:ERYTHROMYCIN_TRANSPORT' nan nan 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*10/*10  + *1/*10' 'CYP2D6*1, CYP2D6*10' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'PEOPLE'
 'OTHER:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ATORVASTATIN' 'HMGCR' 'T' 'rs17671591' 'EFFICACY' 'nan_nan'
 'EFFICACY:LDL-C_RESPONSE' 'PEOPLE' 'DISEASE:CORONARY_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'HMGCR' 'T' 'rs10474433' 'EFFICACY' 'nan_nan'
 'EFFICACY:LDL-C_RESPONSE' 'PEOPLE' 'DISEASE:CORONARY_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'PCSK9' 'T' 'rs11591147' 'EFFICACY' 'nan_nan'
 'EFFICACY:LDL-C_RESPONSE' 'PEOPLE' 'DISEASE:CORONARY_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'APOE' 'T' 'rs429358' 'EFFICACY' 'nan_nan'
 'EFFICACY:LDL-C_RESPONSE' 'PEOPLE' 'DISEASE:CORONARY_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'APOE' 'T' 'rs7412' 'EFFICACY' 'nan_nan'
 'EFFICACY:LDL-C_RESPONSE' 'PEOPLE' 'DISEASE:CORONARY_DISEASE'
 'CAUTION_DOSE_ADJUST']
['SIMVASTATIN' 'ABCG2' 'TT' 'rs2231142' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:EXPOSURE_TO_DRUG' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['FLUVASTATIN' 'ABCG2' 'TT' 'rs2231142' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:EXPOSURE_TO_DRUG' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['PRAVASTATIN' 'NPC1L1' 'CC' 'rs17655652' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:REDUCTION_IN_LDL-C' 'WOMEN' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PRAVASTATIN' 'NPC1L1' 'CC' 'rs17655652' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_LDL-C' 'MEN' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ATORVASTATIN' 'HMGCR' 'GG' 'rs3846662' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_LEVEL_IN_BASAL_STATE_AND_POSSIBLY_IN_RESPONSE_TO_ATORVASTATIN.'
 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'ABCB1' 'GG' 'rs1128503' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' 'OTHER:STROKE'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BETA_BLOCKING_AGENTS, METOPROLOL' 'ADRB1' 'AG + GG' 'rs1801252'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING' 'PEOPLE'
 'DISEASE:HEART_FAILURE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FOLFIRI, FOLFOX, XELOX' 'TYMS' 'del/del' 'rs11280056' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ETOPOSIDE' nan 'GG' 'rs6539870' 'OTHER' 'INCREASED_nan'
 'OTHER:SENSITIVITY_TO_ETOPOSIDE' nan nan 'CAUTION_DOSE_ADJUST']
['"INTERFERON_ALFA-2B, RECOMBINANT", "RIBAVIRIN"' 'ITPA' 'CC' 'rs1127354'
 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['"INTERFERON_ALFA-2B, RECOMBINANT", "RIBAVIRIN"' 'ITPA' 'CC' 'rs1127354'
 'EFFICACY' 'nan_nan' 'EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'CAUTION_DOSE_ADJUST']
['DABIGATRAN' 'CES1' 'GG + GT' 'rs2244613' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'CAUTION_DOSE_ADJUST']
['NAN' 'ABCB1' 'A' 'rs1045642' 'NAN' 'INCREASED_nan'
 'OTHER:LEVEL_OF_APOLIPOPROTEIN_A1' nan nan 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'VKORC1' 'AA' 'rs9934438' 'DOSAGE, EFFICACY, TOXICITY'
 'DECREASED_nan' 'EFFICACY:DOSE_REQUIREMENT' nan nan 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'CYP4F2' 'CC' 'rs2108622' 'OTHER, METABOLISM/PK'
 'DECREASED_nan' 'OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'CYP4F2' 'CT' 'rs2108622' 'OTHER, METABOLISM/PK'
 'DECREASED_nan' 'OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'CAUTION_DOSE_ADJUST']
['ACENOCOUMAROL' 'CYP4F2' 'CC' 'rs2108622' 'DOSAGE, EFFICACY, TOXICITY'
 'DECREASED_nan' 'EFFICACY:DOSAGE_REQUIREMENT' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'CAUTION_DOSE_ADJUST']
['IRINOTECAN' 'SLCO1B1' 'AA + AG' 'rs4149015' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:NEUTROPENIA' 'PEOPLE' 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA'
 'CAUTION_SIDE_EFFECT']
['HMG_COA_REDUCTASE_INHIBITORS' 'SREBF1' 'AA + AG' 'rs11868035' 'OTHER'
 'INCREASED_nan' 'OTHER:TOTAL_CHOLESTEROL' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'CAUTION_DOSE_ADJUST']
['OXYCODONE' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7' 'DOSAGE'
 'INCREASED_nan'
 'PK:OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS'
 nan nan 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'ABCG2' 'TT' 'rs2231142' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:AUC' 'PEOPLE' 'OTHER:NO_DISEASE'
 'CAUTION_DOSE_ADJUST']
['LANSOPRAZOLE' 'CYP2C19' nan 'CYP2C19 INTERMEDIATE METABOLIZER'
 'METABOLISM/PK' 'DECREASED_nan' 'OTHER:GASTRIC_PH' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['IRBESARTAN' 'AGTR1' 'AC + CC' 'rs5186' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BLOOD_PRESSURE_RESPONSE' 'PEOPLE' 'DISEASE:HYPERTENSION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['DEXMEDETOMIDINE' 'ADRA2A' 'G' 'rs1800544' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BISPECTRAL_INDEX_AND_RAMSAY_SEDATION_SCORES, INDICATING_A_LONGER_PERIOD_FOR_FALLING_ASLEEP'
 nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ROSUVASTATIN' 'ABCG2' 'TT' 'rs2231142' 'DOSAGE, METABOLISM/PK'
 'INCREASED_nan' 'PK:AUC' 'PEOPLE' 'OTHER:NO_DISEASE'
 'CAUTION_DOSE_ADJUST']
['ROSUVASTATIN' 'ABCG2' 'GG' 'rs2231142' 'DOSAGE, METABOLISM/PK'
 'DECREASED_nan' 'PK:AUC' 'PEOPLE' 'OTHER:NO_DISEASE'
 'CAUTION_DOSE_ADJUST']
['"INTERFERON_ALFA-2B, RECOMBINANT", "RIBAVIRIN"' 'ITPA' 'CC' 'rs1127354'
 'TOXICITY' 'DECREASED_nan' 'SIDE_EFFECT:HEMOGLOBIN_LEVELS' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ALFENTANIL' 'OPRM1' 'AG + GG' 'rs1799971' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATION' 'PEOPLE' 'DISEASE:PAIN'
 'CAUTION_DOSE_ADJUST']
['LANSOPRAZOLE' 'CYP2C19' nan 'CYP2C19 INTERMEDIATE METABOLIZER'
 'METABOLISM/PK' 'DECREASED_nan' 'OTHER:GASTRIC_PH' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'LRMDA' 'C' 'rs10509373' 'EFFICACY' 'DECREASED_nan'
 'OTHER:RECURRENCE-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BOCEPREVIR, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR' 'IFNL3, IFNL4'
 'CC' 'rs12979860' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CISPLATIN, CYCLOPHOSPHAMIDE' 'TPMT' 'CT' 'rs1142345' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:OVARIAN_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OLANZAPINE, RISPERIDONE' 'DRD2' 'C' 'rs1799978' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:TIME_UNTIL_RESPONSE' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' 'CT + TT' 'rs12248560' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:MAGNITUDE_OF_PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OLANZAPINE, RISPERIDONE' 'DRD2' 'del' 'rs1799732' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:TIME_TO_RESPOND' 'PEOPLE'
 'DISEASE:SCHIZOPHRENIA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE' 'CYP2B6' 'AG + GG'
 'rs2279343' 'EFFICACY' 'INCREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL'
 'CHILDREN' 'DISEASE:RHABDOMYOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OMEPRAZOLE' 'CYP2C19' nan 'CYP2C19 NORMAL METABOLIZER' 'METABOLISM/PK'
 'DECREASED_nan' 'OTHER:GASTRIC_PH' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['IRINOTECAN, PLATINUM_COMPOUNDS' 'NAT2' 'AA' 'rs1799930' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:LUNG_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOXETINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:FLUOXETINE_PLASMA_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['TETRABENAZINE' 'CYP2D6' nan 'CYP2D6 ULTRARAPID_METABOLIZER' 'EFFICACY'
 'nan_nan' 'OTHER:LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT' nan nan
 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLATE_MOFETIL' 'UGT1A9' 'T' 'rs3832043' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['ANTIDEPRESSANTS' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5 + *4/*6'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6'
 '*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7'
 'CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PAROXETINE' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PAROXETINE_PLASMA_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['ANTICHOLINERGIC_AGENTS' 'CYP2C19' nan 'CYP2C19 POOR METABOLIZER'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:SERUM_ANTICHOLINERGIC_ACTIVITY' nan
 nan 'CAUTION_DOSE_ADJUST']
['ANTINEOPLASTIC_AGENTS' 'ABCG2' 'CC + CT' 'rs2231164' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:SURVIVAL' 'PEOPLE'
 'DISEASE:PANCREATIC_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE'
 'CYP2D6' nan 'CYP2D6 NORMAL METABOLIZER' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS' 'PEOPLE'
 'DISEASE:OBSESSIVE_COMPULSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['MYCOPHENOLATE_MOFETIL' 'UGT1A9' 'T' 'rs3832043' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLATE_MOFETIL' 'ABCC2' 'AG' 'rs2273697' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CAPECITABINE' 'DPYD' 'CT' 'rs2297595' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OPIOIDS' 'OPRM1' 'GG' 'rs1799971' 'TOXICITY' 'DECREASED_nan'
 'SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING' 'PEOPLE' 'OTHER:PAIN'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OPIOIDS' 'OPRM1' 'G' 'rs1799971' 'TOXICITY' 'DECREASED_nan'
 'SIDE_EFFECT:ADVERSE_EVENTS' 'PEOPLE' 'OTHER:PAIN'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SORAFENIB' 'KDR' 'AA' 'rs2071559' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['"FOLIC_ACID", "VITAMIN_B-COMPLEX, PLAIN"' 'MTHFR' 'AG + GG' 'rs1801133'
 'EFFICACY' 'nan_nan' 'EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE' 'WOMEN'
 'DISEASE:MIGRAINE_WITH_AURA' 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE' 'CYP2D6'
 nan 'CYP2D6 POOR METABOLIZER' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:ANTIDEPRESSANT_SERUM_LEVELS' 'PEOPLE' 'DISEASE:MENTAL_DISORDERS'
 'CAUTION_DOSE_ADJUST']
['SORAFENIB' 'SLC15A2' 'CC' 'rs2257212' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:HEPATOCELLULAR_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['FLUOROURACIL' 'CCND1' 'AA' 'rs9344' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME-TO-TUMOR_RECURRENCE' nan 'DISEASE:COLONIC_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METFORMIN' nan 'TT' 'rs578427' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['GALANTAMINE' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:DOSE-ADJUSTED_PLASMA_LEVELS' 'PEOPLE'
 'DISEASE:DEMENTIA' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6'
 '*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7'
 'CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METHOTREXATE' 'SLC19A1' 'T' 'rs1051266' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:DRUG-INDUCED_LIVER_INJURY' 'PEOPLE' 'DISEASE:PSORIASIS'
 'CAUTION_SIDE_EFFECT']
['ABT-751' 'UGT1A4' 'AC' 'rs6755571' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:PLASMA_PREDOSE_CONCENTRATION_(CTROUGH)' 'PEOPLE' 'DISEASE:NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['ABT-751' 'UGT1A8' 'CC + CT' 'rs6431558' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:GLUCURONIDATION_METABOLIC_RATIOS' 'PEOPLE' 'DISEASE:NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['IMIPRAMINE' 'CYP2D6' nan 'CYP2D6 POOR METABOLIZER' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['ANTINEOPLASTIC_AGENTS' 'DPYD' 'AA + AG' 'rs1760217' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:SURVIVAL' 'PEOPLE'
 'DISEASE:PANCREATIC_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS' 'SERPINA3' 'AC + CC' 'rs17091162' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:SURVIVAL' 'PEOPLE'
 'DISEASE:PANCREATIC_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *2/*17'
 'CYP2C19*1, CYP2C19*2, CYP2C19*17' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4' 'PEOPLE'
 'DISEASE:CARDIOVASCULAR_DISEASE' 'CAUTION_DOSE_ADJUST']
['METFORMIN' 'SLC47A2' 'AA' 'rs12943590' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['CITALOPRAM, ESCITALOPRAM' nan 'A' 'rs352428' 'EFFICACY' 'nan_nan'
 'EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' nan 'A' 'rs352428' 'EFFICACY' 'nan_nan'
 'EFFICACY:POOR_RESPONSE_AT_6_WEEK_OF_TREATMENT' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['MIDAZOLAM' 'POR' 'CT' 'rs1057868' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:MIDAZOLAM_METABOLIC_RATIOS_BY_45%' nan nan 'CAUTION_DOSE_ADJUST']
['NICOTINE' 'CHRNA3' 'G' 'rs578776' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_LEVEL' nan 'OTHER:TOBACCO_USERS' 'CAUTION_DOSE_ADJUST']
['GALANTAMINE' 'CYP2D6' '*3/*4 + *4/*4 + *4/*5'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:DOSE-ADJUSTED_PLASMA_LEVELS' 'PEOPLE'
 'DISEASE:DEMENTIA' 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'CYP2C19' '*2/*2 + *3/*3 + *2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'EFFICACY' 'INCREASED_nan'
 'OTHER:PLATELET_REACTIVITY' nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METHADONE' 'CRHBP' 'G' 'rs1500' 'OTHER' 'DECREASED_nan'
 'OTHER:RECURRENCE' 'PEOPLE' 'DISEASE:HEROIN_DEPENDENCE'
 'CAUTION_DOSE_ADJUST']
['NALOXONE' 'OPRM1' 'AG + GG' 'rs1799971' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PEAK_CORTISOL_RESPONSE' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' nan 'CYP2D6 NORMAL METABOLIZER' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL3, IFNL4' 'CC' 'rs12979860'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ESCITALOPRAM' 'HTR2C' 'C' 'rs6318' 'EFFICACY' 'DECREASED_nan'
 'DISEASE:PAIN' 'MEN' 'DISEASE:NEUROPATHIC_PAIN'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OXYCODONE' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['OXYCODONE' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:REDUCTION_IN_PAIN_AUC' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['OXYCODONE' 'CYP2D6' nan 'CYP2D6 POOR_METABOLIZER' 'EFFICACY'
 'DECREASED_nan' 'PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PAROXETINE' 'CYP2D6' nan 'CYP2D6 NORMAL METABOLIZER' 'OTHER'
 'INCREASED_nan' 'OTHER:METABOLIC_RATIO_DEM/DOR' 'PEOPLE'
 'DISEASE:ANXIETY_DISORDERS' 'CAUTION_DOSE_ADJUST']
['IRINOTECAN, PLATINUM_COMPOUNDS' 'NAT2' 'AA' 'rs1799931' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:LUNG_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*1/*2 + *1/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'INCREASED_nan' 'OTHER:PLATELET_REACTIVITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ESCITALOPRAM' 'CYP2D6' nan 'CYP2D6 INTERMEDIATE METABOLIZER'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['PAROXETINE' 'CYP2D6' nan 'CYP2D6 POOR METABOLIZER' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:MEDIAN_AUC, PLASMA_HALF-LIFE_AND_STEADY-STATE_PLASMA_CONCENTRATIONS_OF_PAROXETINE'
 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['FLUOXETINE' 'CYP2D6' '*1/*1' 'CYP2D6*1, CYP2D6*1XN' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO' 'CHILDREN'
 'DISEASE:DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*1/*1' 'CYP2D6 NORMAL METABOLIZER' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ESCITALOPRAM' 'CYP2D6' 'AA' 'rs1065852' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RESPONSE_AND_REMISSION_RATE' 'PEOPLE'
 'DISEASE:DEPRESSIVE_DISORDER' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' nan 'T' 'rs6968865' 'DOSAGE' 'INCREASED_nan'
 'OTHER:COFFEE_CONSUMPTION' nan nan 'CAUTION_DOSE_ADJUST']
['AZATHIOPRINE, MERCAPTOPURINE' 'TPMT' nan 'TPMT INTERMEDIATE_METABOLIZER'
 'EFFICACY, TOXICITY, METABOLISM/PK' 'INCREASED_nan' 'PK:6-TG_LEVELS'
 'PEOPLE' 'DISEASE:INFLAMMATORY_BOWEL_DISEASES'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'CYP1A1' 'T' 'rs2472297' 'DOSAGE' 'INCREASED_nan'
 'OTHER:COFFEE_CONSUMPTION' nan nan 'CAUTION_DOSE_ADJUST']
['ANTHRACYCLINES_AND_RELATED_SUBSTANCES' 'ABCC2' 'AG + GG' 'rs2273697'
 'EFFICACY' 'INCREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'PEOPLE'
 'OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['SORAFENIB' 'KDR' 'TT' 'rs1870377' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:HEPATOCELLULAR_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TACROLIMUS' 'CYP3A4' 'AG' 'rs35599367' 'OTHER' 'INCREASED_nan'
 'PK:CREATININE_CLEARANCE' 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION'
 'CAUTION_DOSE_ADJUST']
['ANTHRACYCLINES_AND_RELATED_SUBSTANCES' 'ABCC2' 'TT' 'rs3740066'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'PON1' 'CC' 'rs662' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(PR)_AT_1_MONTH_AND_AT_6_MONTHS_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)'
 'PEOPLE' 'DISEASE:MYOCARDIAL_ISCHEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'NR1I2' 'TT' 'rs2276707' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METOPROLOL' 'CYP2D6' '*1/*2' 'CYP2D6*1, CYP2D6*2' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:HEART_RATE' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SORAFENIB' 'KDR' 'GG' 'rs2071559' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYTARABINE' 'GLI1' 'AA' 'rs2228224' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'PEOPLE'
 'OTHER:ACUTE_MYELOID_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYTARABINE' 'ARHGAP9, GLI1' 'GT + TT' 'rs2229300' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:ACUTE_MYELOID_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SORAFENIB' 'KDR' 'TT' 'rs1870377' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:HEPATOCELLULAR_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'CELSR2, PSRC1' 'T' 'rs602633' 'METABOLISM/PK' 'nan_nan'
 'PK:BASELINE_LDL_CHOLESTEROL' 'PEOPLE' 'DISEASE:VASCULAR_DISEASES'
 'CAUTION_DOSE_ADJUST']
['METHOTREXATE' 'SLCO1B1' 'G' 'rs4149081' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:CLEARANCE' 'PEOPLE'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_DOSE_ADJUST']
['MIRTAZAPINE' 'CYP2D6' '*4/*4 + *4/*6' 'CYP2D6*1, CYP2D6*4, CYP2D6*6'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['TROGLITAZONE' nan 'C' 'rs10811661' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BETA_CELL_FUNCTION' 'PEOPLE'
 'OTHER:HIGH_RISK_FOR_TYPE_2_DIABETES' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NEVIRAPINE' 'CYP2B6' 'T' 'rs3745274' 'METABOLISM/PK' 'INCREASED_nan'
 'OTHER:PLASMA_LEVEL' 'PEOPLE' 'DISEASE:HIV_INFECTIOUS_DISEASE'
 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*3' 'CYP2C19*1, CYP2C19*3' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CAFFEINE' 'DRD2' 'GG' 'rs1110976' 'OTHER' 'DECREASED_nan'
 'SIDE_EFFECT:ANXIETY' 'PEOPLE' 'OTHER:NO_DISEASE' 'CAUTION_DOSE_ADJUST']
['NAN' nan 'C' 'rs1111875' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:INSULIN_SECRETION_AT_BASELINE' 'PEOPLE'
 'OTHER:HIGH_RISK_OF_TYPE_2_DIABETES' 'CAUTION_DOSE_ADJUST']
['FLUOXETINE' 'CYP2D6' '*4 + *6' 'CYP2D6*1, CYP2D6*4, CYP2D6*6'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['CITALOPRAM' 'CYP2C19' '*2/*2 + *2/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['PLATINUM_COMPOUNDS' 'SLC22A2' 'CT + TT' 'rs316003' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CITALOPRAM, ESCITALOPRAM' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO'
 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['HYDROCHLOROTHIAZIDE' nan 'CC + CT' 'rs17137967' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:FASTING_GLUCOSE' 'PEOPLE'
 'DISEASE:HYPERTENSION' 'CAUTION_SIDE_EFFECT']
['DIRECT_ACTING_ANTIVIRALS' 'IFNL4' 'GG' 'rs11322783' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PLATINUM_COMPOUNDS' 'APLF' 'CCGG/CCGG + CCGG/del' 'rs3213239' 'EFFICACY'
 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, RIBAVIRIN' 'IFNL3' 'GG' 'rs8099917' 'EFFICACY'
 'nan_nan' 'EFFICACY:LACK_OF_TREATMENT_RESPONSE' 'PEOPLE'
 'DISEASE:HEPATITIS_C_VIRUS_INFECTION' 'CAUTION_DOSE_ADJUST']
['PLATINUM_COMPOUNDS' 'ABCG2' 'GG' 'rs1448784' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE' 'OTHER:LUNG_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['BOCEPREVIR, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL3, IFNL4' 'CC'
 'rs12979860' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OPIUM_ALKALOIDS_AND_DERIVATIVES' 'CHRNA5' 'GG' 'rs660652' 'TOXICITY'
 'INCREASED_nan' 'DISEASE:TOBACCO_USE_DISORDER' 'PEOPLE' 'DISEASE:PAIN'
 'CAUTION_SIDE_EFFECT']
['ACE_INHIBITORS, PLAIN' 'ABO' 'GT + TT' 'rs495828' 'TOXICITY' 'nan_nan'
 'DISEASE:COUGH' nan nan 'CAUTION_DOSE_ADJUST']
['GLICLAZIDE' 'KCNJ11' 'CT + TT' 'rs5219' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C' 'PEOPLE'
 'DISEASE:DIABETES_MELLITUS_T2' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'CYP2C19' '*1 + *17' 'CYP2C19*1, CYP2C19*2, CYP2C19*17'
 'EFFICACY' 'DECREASED_nan' 'OTHER:PLATELET_REACTIVITY' 'PEOPLE'
 'DISEASE:CORONARY_ARTERY_DISEASE' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NORTRIPTYLINE' 'CYP2D6' '*4/*4' 'CYP2D6*1, CYP2D6*4' 'METABOLISM/PK'
 'DECREASED_nan'
 'PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE' 'HEALTHY'
 nan 'CAUTION_DOSE_ADJUST']
['NAN' 'NQO1' 'AA' 'rs1800566' 'OTHER' 'nan_nan'
 'OTHER:SIGNIFICANTLY_SHORTER_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['BUSULFAN' 'CYP2C9' '*2 + *3' 'CYP2C9*1, CYP2C9*2, CYP2C9*3'
 'METABOLISM/PK' 'INCREASED_nan' 'PK:METABOLIC_RATIO' 'CHILDREN'
 'DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT' 'CAUTION_DOSE_ADJUST']
['HYDROCHLOROTHIAZIDE' 'ACE'
 'ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC'
 'rs1799752' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_BLOOD_PRESSURE' 'WOMEN'
 'DISEASE:ESSENTIAL_HYPERTENSION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['FLUOROURACIL' 'TYMS' 'TTAAAGTTA/TTAAAGTTA' 'rs11280056' 'EFFICACY'
 'DECREASED_nan' 'DISEASE:EVENT-FREE_SURVIVAL, DISEASE:OVERALL_SURVIVAL'
 'PEOPLE' 'DISEASE:RECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['AXITINIB, SORAFENIB' 'HIF1A' 'CT' 'rs11549465' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SORAFENIB' 'KDR' 'AA' 'rs2071559' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP2C9' '*2' 'CYP2C9*1, CYP2C9*2' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME_IN_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*5/*10'
 'CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*1/*2' 'CYP2C19*1, CYP2C19*2' 'OTHER'
 'INCREASED_nan' 'OTHER:PLATELET_AGGREGATION_WITH_ADP' 'PEOPLE'
 'DISEASE:ACUTE_CORONARY_SYNDROME' 'CAUTION_DOSE_ADJUST']
['TAMOXIFEN' 'CYP2D6' '*3 + *4 + *5 + *10 + *41'
 'CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SULFONAMIDES, UREA_DERIVATIVES' 'KCNJ11' 'CT + TT' 'rs5219' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT'
 'PEOPLE' 'DISEASE:DIABETES_MELLITUS_T2' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOXETINE' 'CYP2D6' '*1/*1xN' 'CYP2D6*1, CYP2D6*1XN' 'METABOLISM/PK'
 'DECREASED_nan' 'PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['VERAPAMIL' 'KCNIP1, KCNMB1' 'CT + TT' 'rs11739136' 'EFFICACY' 'nan_nan'
 'EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL' 'PEOPLE'
 'DISEASE:HYPERTENSION' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL4' 'TT/TT'
 'rs11322783' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OSIMERTINIB' 'CYP2C9' 'AC' 'rs1057910' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'OTHER:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['METFORMIN' 'AMHR2' 'G' 'rs784892' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:METFORMIN_SECRETORY_CLEARANCE' 'HEALTHY' nan 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLATE_MOFETIL' 'SLCO1B3' 'GG' 'rs4149117' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['CARBOPLATIN, GEMCITABINE' 'RRM1' 'GG' 'rs9937' 'TOXICITY' 'nan_RISK'
 'DISEASE:HEMATOLOGIC_DISORDER' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'CAUTION_DOSE_ADJUST']
['METFORMIN' 'SLC22A1' 'A' 'rs628031' 'TOXICITY, METABOLISM/PK' 'nan_nan'
 'SIDE_EFFECT:GASTROINTESTINAL_TOXICITY' 'PEOPLE'
 'DISEASE:DIABETES_MELLITUS_T2' 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2D6' '*4' 'CYP2D6*1, CYP2D6*4' 'OTHER, METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_NORTRIPTYLINE' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2D6' '*10' 'CYP2D6*1, CYP2D6*10'
 'OTHER, METABOLISM/PK' 'INCREASED_nan' 'PK:PLASMA_NORTRIPTYLINE' 'PEOPLE'
 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['AMITRIPTYLINE' 'CYP2C19' '*1/*3 + *2/*3'
 'CYP2C19*1, CYP2C19*2, CYP2C19*3' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT'
 'PEOPLE' 'DISEASE:MENTAL_DISORDERS' 'CAUTION_DOSE_ADJUST']
['MYCOPHENOLATE_MOFETIL' 'SLCO1B3' 'AA' 'rs7311358' 'METABOLISM/PK'
 'INCREASED_nan'
 'PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['SALBUTAMOL' 'THRB' 'A' 'rs892940' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BRONCHODILATOR_RESPONSE_(BDR)' 'CHILDREN' 'DISEASE:ASTHMA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['TAMOXIFEN' 'CYP2D6' '*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41'
 'CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'WOMEN'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ANTINEOPLASTIC_AGENTS, TAMOXIFEN' 'CYP2D6' '*10/*10'
 'CYP2D6*1, CYP2D6*10' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:EVENT-FREE_SURVIVAL' 'WOMEN' 'DISEASE:BREAST_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CLOPIDOGREL' 'CYP2C19' '*1/*1' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'KDR' 'TT' 'rs1870377' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES' 'TPMT'
 '*1/*3A + *3A/*3C' 'TPMT*1, TPMT*3A, TPMT*3C' 'TOXICITY, METABOLISM/PK'
 'INCREASED_nan'
 'PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES' 'PEOPLE'
 'DISEASE:INFLAMMATORY_BOWEL_DISEASES' 'CAUTION_SIDE_EFFECT']
['TACROLIMUS' 'CYP3A4' 'AG + GG' 'rs4646437' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['NAN' 'CYP4A11' 'AG + GG' 'rs1126742' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:HDL-C_CONCENTRATION' 'WOMEN' nan 'CAUTION_DOSE_ADJUST']
['PEMETREXED' 'SLC19A1' 'TT' 'rs914232' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CITALOPRAM' 'CYP2C19' '*2/*2 + *2/*3' 'CYP2C19*1, CYP2C19*2, CYP2C19*3'
 'METABOLISM/PK' 'INCREASED_nan'
 'PK:AUC_OF_THE_S-ETIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT)' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['PEMETREXED' 'SLC19A1' 'AA + AG' 'rs1051298' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CETUXIMAB' 'FCGR2A' 'GG' 'rs1801274' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PEMETREXED' 'MTHFR' 'AA + AG' 'rs1801133' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEMETREXED' 'SLC19A1' 'GG + GT' 'rs3788189' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SIROLIMUS' 'ABCB1' 'AA + AG' 'rs1045642' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:TOTAL_CHOLESTEROL' 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION'
 'CAUTION_SIDE_EFFECT']
['IRINOTECAN' 'UGT1A1' '*28/*28 + *6/*6 + *6/*28'
 'UGT1A1*1, UGT1A1*6, UGT1A1*28' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NALOXONE' 'OPRM1' 'AG + GG' 'rs1799971' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:CORTISOL_RESPONSE' nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ANTIARRHYTHMICS, CLASS_I_AND_III' nan 'GT + TT' 'rs10033464' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:RECURRENCE' 'PEOPLE'
 'DISEASE:ATRIAL_FIBRILLATION' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['SIROLIMUS' 'ABCB1' 'AA + AG' 'rs1045642' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_SIDE_EFFECT']
['SIROLIMUS' 'ABCB1' 'AA' 'rs1128503' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:TRIGLYCERIDES' 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION'
 'CAUTION_SIDE_EFFECT']
['TACROLIMUS' 'CYP3A5' '*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7'
 'CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7' 'EFFICACY' 'nan_nan'
 'EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['TACROLIMUS' 'CYP2C8' '*1/*1' 'CYP2C8*1, CYP2C8*3' 'EFFICACY' 'nan_nan'
 'EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE' 'PEOPLE'
 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['FLURBIPROFEN, IRINOTECAN' 'UGT1A1' '*1/*36' 'UGT1A1*1, UGT1A1*36'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'AA + AG' 'rs1801265' 'TOXICITY'
 'DECREASED_nan' 'SIDE_EFFECT:DRUG_TOXICITY' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CETUXIMAB' 'FCGR3A' 'CC' 'rs396991' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:ANTIBODY-DEPENDENT_CELLULAR_CYTOTOXICITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CAPECITABINE' 'ENOSF1' 'TT' 'rs2612091' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'PEOPLE' 'OTHER:COLORECTAL_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CARBOPLATIN, PACLITAXEL' 'OPRM1' 'GG + GT' 'rs544093' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'OTHER:OVARIAN_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'ASPH' 'T' 'rs4379440' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME_IN_THERAPEUTIC_RANGE' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CAPECITABINE, FLUOROURACIL' 'DPYD' 'AT' 'rs67376798' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:DRUG_TOXICITY' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'CAUTION_SIDE_EFFECT']
['HMG_COA_REDUCTASE_INHIBITORS' 'CETP' 'A' 'rs3764261'
 'EFFICACY, METABOLISM/PK' 'INCREASED_nan' 'OTHER:HDL_CHOLESTEROL' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PYRIMIDINE_ANALOGUES' 'MTHFR' 'AA + AC' 'rs1801133' 'NAN'
 'INCREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'OTHER:COLORECTAL_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['METHOTREXATE' 'ITPA' 'A' 'rs1127354' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES' 'PEOPLE'
 'DISEASE:RHEUMATOID_ARTHRITIS' 'CAUTION_DOSE_ADJUST']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'CTLA4' 'A'
 'rs231775' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS'
 nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CAFFEINE' nan 'T' 'rs4410790' 'OTHER' 'nan_nan'
 'OTHER:HABITUAL_CONSUMPTION' nan nan 'CAUTION_DOSE_ADJUST']
['PLATINUM' 'ERCC5' 'GG' 'rs17655' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SURVIVAL' 'WOMEN' 'DISEASE:OVARIAN_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PLATINUM' 'ERCC5' 'GG' 'rs17655' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:SURVIVAL' 'WOMEN' 'DISEASE:OVARIAN_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CAFFEINE' 'CYP1A1' 'T' 'rs2470893' 'OTHER' 'nan_nan'
 'OTHER:HABITUAL_CONSUMPTION' nan nan 'CAUTION_DOSE_ADJUST']
['MIDAZOLAM' 'POR' 'TT' 'rs1057868' 'OTHER, METABOLISM/PK' 'INCREASED_nan'
 'PK:METABOLIC_RATIO_OF_MIDAZOLAM' nan nan 'CAUTION_DOSE_ADJUST']
['METHOTREXATE' 'ITPA' 'A' 'rs1127354' 'EFFICACY' 'nan_nan'
 'EFFICACY:RESPONSE_TO_METHOTREXATE' 'PEOPLE'
 'DISEASE:RHEUMATOID_ARTHRITIS' 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP4F2' 'GG' 'rs2189784' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:TIME_TO_THERAPEUTIC_INR' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PLATINUM_COMPOUNDS' 'WIF1' 'GG + GT' 'rs10878232' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PLATINUM_COMPOUNDS' 'WNT5B' 'AG + GG' 'rs12819505' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PLATINUM_COMPOUNDS' 'AXIN2' 'AA + AC' 'rs4541111' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MERCAPTOPURINE, METHOTREXATE' 'PACSIN2' 'T' 'rs2413739' 'TOXICITY'
 'INCREASED_nan' 'SIDE_EFFECT:GI_TOXICITY' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['MERCAPTOPURINE' 'SLCO1B1' 'T' 'rs11045879' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:GI_TOXICITY' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'CAUTION_SIDE_EFFECT']
['MERCAPTOPURINE, METHOTREXATE' 'ITPA' 'CC' 'rs1127354' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:EVENT_FREE_SURVIVAL' 'CHILDREN'
 'DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PLATINUM_COMPOUNDS' 'CXXC4' 'AA + AG' 'rs4413407' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL3' 'T'
 'rs8099917' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['AMPHETAMINE' 'DRD2' 'AA' 'rs12364283' 'EFFICACY' 'DECREASED_nan'
 'OTHER:STOP_REACTION_TIME' 'HEALTHY' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['MYCOPHENOLATE_MOFETIL' 'UGT1A9' 'A' 'rs6714486' 'METABOLISM/PK'
 'nan_nan'
 'PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['PLATINUM_COMPOUNDS' 'AXIN2' 'CC + CG' 'rs11868547' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['MYCOPHENOLATE_MOFETIL' 'UGT1A9' 'T' 'rs17868320' 'METABOLISM/PK'
 'nan_nan'
 'PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)'
 'PEOPLE' 'DISEASE:KIDNEY_TRANSPLANTATION' 'CAUTION_DOSE_ADJUST']
['FOLLITROPIN_BETA, THYROTROPIN_ALFA, UROFOLLITROPIN' 'FSHR' 'T' 'rs6166'
 'EFFICACY, METABOLISM/PK' 'nan_nan'
 'EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION' nan nan
 'CAUTION_DOSE_ADJUST']
['CLOPIDOGREL' 'ABCB1' 'AG' 'rs1045642' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' nan nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'CYP4F2' 'CT + TT' 'rs2108622' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_MK-4_CONCENTRATION' 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['ALENDRONATE' 'VDR' 'CC' 'rs1544410' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:BONE_MINERAL_DENSITY' 'PEOPLE' 'DISEASE:OSTEOPOROSIS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FENOFIBRATE' 'PPARA' 'TT' 'rs135543' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_FASTING_LDL-C' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FENOFIBRATE' 'PPARA' 'CC + CT' 'rs9626730' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:REDUCTION_IN_FASTING_IL-2' nan nan
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'CYP4F2' 'CT + TT' 'rs2108622' 'DOSAGE' 'DECREASED_nan'
 'OTHER:WARFARIN_SENSITIVITY_INDEX_(INR/CPSS)' 'CHILDREN' nan
 'CAUTION_DOSE_ADJUST']
['NAN' 'VDR' 'CC' 'rs1544410' 'NAN' 'DECREASED_nan'
 'EFFICACY:BONE_MINERAL_DENSITY' 'PEOPLE' nan 'CAUTION_DOSE_ADJUST']
['FENOFIBRATE' 'PPARA' 'TT' 'rs135550' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_FASTING_LDL-C' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ALENDRONATE' 'VDR' 'CC' 'rs1544410' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:URINARY_DPD/CR_LEVELS' 'PEOPLE' 'DISEASE:OSTEOPOROSIS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['EXEMESTANE' 'CYP19A1' 'TT' 'rs7176005' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS'
 'WOMEN' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['ATENOLOL' 'PROX1' 'C' 'rs340874' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:GLUCOSE_ELEVATION' 'PEOPLE' 'DISEASE:HYPERTENSION'
 'CAUTION_SIDE_EFFECT']
['SUNITINIB' 'CYP3A5' 'CT + TT' 'rs776746' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METOPROLOL' 'CYP2D6' 'GG' 'rs1065852' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:HEART_RATE' 'PEOPLE' nan 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CONJUGATED_ESTROGENS, MEDROXYPROGESTERONE' 'VDR' 'TT' 'rs1544410'
 'EFFICACY' 'INCREASED_nan' 'OTHER:SPINE_BONE_MINERAL_DENSITY' nan nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METFORMIN' 'SLC47A1' 'CC' 'rs2252281' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_TO_METFORMIN' 'PEOPLE' 'DISEASE:DIABETES_MELLITUS_T2'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['METFORMIN' 'SLC47A1' 'CC' 'rs2252281' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:RESPONSE_TO_METFORMIN' 'HEALTHY' nan
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['INTERFERONS, RIBAVIRIN' 'BCL2' 'T' 'rs1800477' 'EFFICACY'
 'INCREASED_nan'
 'EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4)'
 'PEOPLE' 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN' 'KRAS' 'T'
 'rs112445441' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOROURACIL' nan 'AA' 'rs2960436' 'EFFICACY' 'nan_nan'
 'OTHER:BETTER_SURVIVAL_OUTCOME' 'PEOPLE' 'DISEASE:STOMACH_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['FLUOROURACIL' 'IGFBP3' 'TT' 'rs2854744' 'EFFICACY' 'nan_nan'
 'OTHER:BETTER_SURVIVAL_OUTCOME' 'PEOPLE' 'DISEASE:STOMACH_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['NAN' 'VDR' 'AA + AG' 'rs2228570' 'NAN' 'DECREASED_nan'
 'EFFICACY:BONE_MINERAL_DENSITY' nan nan 'CAUTION_DOSE_ADJUST']
['WARFARIN' 'CYP2C9' 'A' 'rs7900194' 'DOSAGE, METABOLISM/PK' 'nan_nan'
 'OTHER:WARFARIN_VARIABILITY' nan nan 'CAUTION_DOSE_ADJUST']
['SUNITINIB' 'NR1I2' 'TT' 'rs3814055' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['AMPHETAMINE' 'OPRM1' 'TT' 'rs510769' 'OTHER' 'DECREASED_nan'
 'OTHER:STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['SUNITINIB' 'ABCG2' 'CT' 'rs2231137' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'LRP5' 'T' 'rs3736228' 'NAN' 'DECREASED_nan'
 'OTHER:BONE_MINERAL_DENSITY' nan nan 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'NHLH1' 'CT + TT' 'rs11265375' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' nan 'A' 'rs4355801' 'NAN' 'DECREASED_nan'
 'OTHER:LUMBAR_SPINE_BONE_MINERAL_DENSITY' nan nan 'CAUTION_DOSE_ADJUST']
['AMPHETAMINE' 'OPRM1' 'CC' 'rs2281617' 'OTHER' 'INCREASED_nan'
 'OTHER:EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG)' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'SEMA6A' 'A' 'rs3806915' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['PEGINTERFERON_ALFA-2B, RIBAVIRIN' 'IFNL3, IFNL4' 'CC' 'rs12979860'
 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)' 'PEOPLE'
 'DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ONDANSETRON' 'SLC6A4' 'AA' 'rs1042173' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:TREATMENT_RESPONSE_AMONG_PATIENTS_CARRYING_THE_SLC6A4_PROMOTER_LENGTH_POLYMORPHISM_LONG/LONG_GENOTYPE'
 'PEOPLE' 'DISEASE:ALCOHOL_ABUSE' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['ASPIRIN' 'IL4' 'TT' 'rs2243250' 'OTHER' 'DECREASED_nan'
 'SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA' 'PEOPLE' 'DISEASE:ASTHMA'
 'CAUTION_DOSE_ADJUST']
['METFORMIN' 'AMHR2' 'G' 'rs784892' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:POST-HBA1C_LEVELS' 'PEOPLE' 'DISEASE:DIABETES_MELLITUS_T2'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'VKORC1' 'TT' 'rs9923231' 'EFFICACY' 'nan_nan'
 'EFFICACY:SHORTER_TIME_TO_FIRST_THERAPEUTIC_INR_AND_TIME_TO_FIRST_INR>4'
 'CHILDREN' nan 'CAUTION_DOSE_ADJUST']
['CISPLATIN' 'SLC22A1' 'CG + GG' 'rs683369' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'OTHER:NEOPLASM_OF_ESOPHAGUS'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CLOPIDOGREL' 'PON1' 'CC' 'rs854552' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PLATELET_REACTIVITY' 'PEOPLE' 'OTHER:CORONARY_ARTERY_DISEASE'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CISPLATIN' 'PPARD' 'AG + GG' 'rs2038067' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE' 'OTHER:NEOPLASM_OF_ESOPHAGUS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['WARFARIN' 'VKORC1' 'T' 'rs9923231' 'EFFICACY' 'INCREASED_nan'
 "EFFICACY:PROPERTION_OF_THE_FIRST_6_MONTHS'_TREATMENT_TIME_SPENT_WITHIN_THE_TARGET_INR_RANGE_(PTIR)"
 'CHILDREN' nan 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['LITHIUM' 'GSK3B' 'AA' 'rs334558' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RESPONSE' 'PEOPLE' 'DISEASE:BIPOLAR_DISORDER'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ASPIRIN, CLOPIDOGREL' 'PON1' 'CT + TT' 'rs662' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:NON-RESPONSIVENESS' 'PEOPLE'
 'DISEASE:ANGINA_PECTORIS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['FLUOROURACIL, RADIOTHERAPY' 'KDR' 'AA' 'rs1870377' 'TOXICITY' 'nan_RISK'
 'SIDE_EFFECT:MUCOSITIS' 'PEOPLE' 'DISEASE:RECTAL_NEOPLASMS'
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'CYP7A1' 'TT' 'rs3808607' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:MEAN_PERCENTAGE_REDUCTION_OF_TRIGLYCERIDES_LEVEL' 'PEOPLE'
 'DISEASE:HYPERLIPIDEMIAS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CANGRELOR' 'P2RY12' 'G' 'rs6787801' 'OTHER' 'nan_nan'
 'OTHER:5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO' nan nan
 'CAUTION_DOSE_ADJUST']
['NAN' 'APOC1, APOE' 'A' 'rs445925' 'METABOLISM/PK' 'nan_nan'
 'PK:BASELINE_LDL_CHOLESTEROL' 'PEOPLE' 'DISEASE:VASCULAR_DISEASES'
 'CAUTION_DOSE_ADJUST']
['SUNITINIB' 'FGFR2' 'AA' 'rs2981582' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'FLT4' 'CC + CT' 'rs307826' 'EFFICACY' 'DECREASED_nan'
 'DISEASE:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'NR1I3' 'AA + AG' 'rs2307424' 'EFFICACY' 'DECREASED_nan'
 'DISEASE:OVERALL_SURVIVAL' 'PEOPLE' 'DISEASE:RENAL_CELL_CARCINOMA'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'FADS1, FEN1, MIR611, TMEM258' 'T' 'rs174541' 'METABOLISM/PK'
 'nan_nan' 'PK:BASELINE_LDL_CHOLESTEROL' 'PEOPLE'
 'DISEASE:VASCULAR_DISEASES' 'CAUTION_DOSE_ADJUST']
['NAN' nan 'C' 'rs258494' 'METABOLISM/PK' 'nan_nan'
 'PK:BASELINE_LDL_CHOLESTEROL' 'PEOPLE' 'DISEASE:VASCULAR_DISEASES'
 'CAUTION_DOSE_ADJUST']
['NAN' 'LDLR' 'T' 'rs6511720' 'OTHER' 'nan_nan'
 'PK:BASELINE_LDL_CHOLESTEROL' 'PEOPLE' 'DISEASE:VASCULAR_DISEASES'
 'CAUTION_DOSE_ADJUST']
['FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY' 'GSTP1' 'GG'
 'rs1695' 'EFFICACY' 'DECREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:RECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'NR1I3' 'AA' 'rs4073054' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'FLT4' 'AA + AC' 'rs307821' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['SUNITINIB' 'ABCB1' 'AG + GG' 'rs1128503' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:RENAL_CELL_CARCINOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['OLANZAPINE' 'CYP1A1' 'T' 'rs2472297' 'METABOLISM/PK' 'nan_nan'
 "PK:25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO" 'PEOPLE'
 'DISEASE:PSYCHOTIC_DISORDER' 'CAUTION_DOSE_ADJUST']
['BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN' 'MGAT4A' 'G'
 'rs885036' 'EFFICACY' 'INCREASED_nan' 'DISEASE:PROGRESSION-FREE_SURVIVAL'
 'PEOPLE' 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['BEVACIZUMAB, CAPECITABINE, OXALIPLATIN' 'MGAT4A' 'G' 'rs885036'
 'EFFICACY' 'DECREASED_nan' 'DISEASE:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:COLORECTAL_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ASPIRIN, CLOPIDOGREL' 'PEAR1' 'G' 'rs2644592' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'PEAR1' 'C' 'rs11264580' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'PEAR1' 'TT' 'rs57731889' 'EFFICACY' 'nan_nan'
 'EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN, BEZAFIBRATE' 'APOE' 'AT + TT' 'rs449647' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:LIPID-LOWERING_EFFECT' 'PEOPLE'
 'DISEASE:HYPERLIPIDEMIAS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['HALOPERIDOL' 'SLC6A5' 'AA' 'rs2298826' 'TOXICITY' 'nan_nan'
 'SIDE_EFFECT:MOTOR_SIDE_EFFECTS' 'PEOPLE' 'DISEASE:SCHIZOPHRENIA'
 'CAUTION_DOSE_ADJUST']
['OLANZAPINE' 'AHR' 'T' 'rs4410790' 'METABOLISM/PK' 'nan_nan'
 "PK:29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO" 'PEOPLE'
 'DISEASE:PSYCHOTIC_DISORDER' 'CAUTION_DOSE_ADJUST']
['ASPIRIN, CLOPIDOGREL' 'PEAR1' 'T' 'rs3737224' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'CAUTION_DOSE_ADJUST']
['VENLAFAXINE' 'CYP2D6' 'del' 'rs5030655' 'METABOLISM/PK' 'nan_nan'
 'PK:IMPAIRED_METABOLIC_ACTIVITY' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_DOSE_ADJUST']
['CISPLATIN, DOXORUBICIN' 'CASP3' 'C' 'rs2720376' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:OSTEOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CISPLATIN, DOXORUBICIN' 'CYP3A4' 'A' 'rs4646437' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:OSTEOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['NAN' 'GLI1' 'CC' 'rs2228226' 'EFFICACY' 'DECREASED_nan'
 'EFFICACY:RECURRENCE_FREE_SURVIVAL' 'PEOPLE' 'DISEASE:COLONIC_NEOPLASMS'
 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['ESCITALOPRAM' 'CYP1A2' 'T' 'rs4646425' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:FATIGUE' 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'CAUTION_SIDE_EFFECT']
['ESCITALOPRAM' nan 'A' 'rs2069521' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:FATIGUE' 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'CAUTION_SIDE_EFFECT']
['ASPIRIN, CLOPIDOGREL' 'PEAR1' 'T' 'rs41273215' 'EFFICACY' 'nan_nan'
 'EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY' nan nan
 'CAUTION_DOSE_ADJUST']
['ESCITALOPRAM' 'CYP1A2' 'C' 'rs4646427' 'TOXICITY' 'INCREASED_nan'
 'DISEASE:FATIGUE' 'PEOPLE' 'DISEASE:MAJOR_DEPRESSIVE_DISORDER'
 'CAUTION_SIDE_EFFECT']
['ESCITALOPRAM' nan 'A' 'rs2069521' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:NAUSEA/VOMITING' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_SIDE_EFFECT']
['ESCITALOPRAM' 'CYP1A2' 'T' 'rs4646425' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:NAUSEA/VOMITING' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_SIDE_EFFECT']
['ESCITALOPRAM' 'CYP1A2' 'C' 'rs4646427' 'TOXICITY' 'INCREASED_nan'
 'SIDE_EFFECT:NAUSEA/VOMITING' 'PEOPLE'
 'DISEASE:MAJOR_DEPRESSIVE_DISORDER' 'CAUTION_SIDE_EFFECT']
['CLOPIDOGREL' 'CYP1A2' 'AA + AC' 'rs762551' 'EFFICACY, METABOLISM/PK'
 'DECREASED_nan' 'EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY' 'PEOPLE'
 'OTHER:CIGARETTE_SMOKERS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOPHOSPHAMIDE, DOXORUBICIN' 'NQO1' 'A' 'rs1800566' 'EFFICACY'
 'nan_nan'
 'EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)'
 'PEOPLE' 'DISEASE:BREAST_NEOPLASMS' 'CAUTION_DOSE_ADJUST']
['CISPLATIN, DOXORUBICIN' 'ABCC5' 'G' 'rs939338' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:OSTEOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CISPLATIN, DOXORUBICIN' 'FASLG' 'T' 'rs763110' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:OSTEOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CISPLATIN, DOXORUBICIN' 'MSH2' 'C' 'rs4638843' 'EFFICACY'
 'DECREASED_nan' 'EFFICACY:PROGRESSION-FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:OSTEOSARCOMA' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['FEXOFENADINE' 'SLCO2B1' 'T' 'rs2306168' 'METABOLISM/PK' 'DECREASED_nan'
 'PK:_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE' 'HEALTHY' nan
 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2B6' 'TT' 'rs3745274' 'METABOLISM/PK' 'INCREASED_nan'
 'PK:PLASMA_CONCENTRATION_(P<0.001)' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'CYP2A6' 'AC + CC' 'rs8192726' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATION_(P=0.028)' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL' 'CYP3A4' 'CC' 'rs2740574'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:DISEASE_FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL' 'CYP3A4' 'CT' 'rs2740574'
 'EFFICACY' 'DECREASED_nan' 'EFFICACY:DISEASE_FREE_SURVIVAL' 'PEOPLE'
 'DISEASE:BREAST_NEOPLASMS' 'LIKELIHOOD_THERAPEUTIC_FAILURE']
['NAN' 'ADH1B' 'A' 'rs1789891' 'OTHER' 'INCREASED_nan'
 'DISEASE:ALCOHOL_ABUSE' nan nan 'CAUTION_DOSE_ADJUST']
['EFAVIRENZ' 'UGT2B7' 'CC + CT' 'rs7439366' 'METABOLISM/PK'
 'INCREASED_nan' 'PK:PLASMA_CONCENTRATION' 'PEOPLE'
 'DISEASE:HIV_INFECTIOUS_DISEASE' 'CAUTION_DOSE_ADJUST']
['NAN' 'FGFBP1' 'CC' 'rs2245964' 'OTHER' 'INCREASED_nan'
 'OTHER:BONE_MINERAL_DENSITY' nan nan 'CAUTION_DOSE_ADJUST']
['NAN' 'FGFBP1' 'TT' 'rs16892645' 'OTHER' 'INCREASED_nan'
 'OTHER:BONE_MINERAL_DENSITY' nan nan 'CAUTION_DOSE_ADJUST']
['ATORVASTATIN' 'SLCO1B1' 'GG' 'rs2306283' 'EFFICACY' 'INCREASED_nan'
 'EFFICACY:REDUCTION_IN_LDL' 'PEOPLE' 'DISEASE:HYPERCHOLESTEROLEMIA'
 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['CISPLATIN, FLUOROURACIL' 'ERCC1' 'AA + AC' 'rs3212986' 'EFFICACY'
 'INCREASED_nan' 'EFFICACY:OVERALL_SURVIVAL' 'PEOPLE'
 'DISEASE:NEOPLASM_OF_ESOPHAGUS' 'LIKELIHOOD_THERAPEUTIC_SUCCESS']
['WARFARIN' 'VKORC1' 'T' 'rs9923231' 'EFFICACY' 'nan_nan'
 'EFFICACY:TIME_TO_THERAPEUTIC_INR' 'PEOPLE' 'DISEASE:ATRIAL_FIBRILLATION'
 'CAUTION_DOSE_ADJUST']
